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Abstract 
Norovirus is recognized as the major cause of outbreaks of gastroenteritis world-wide, 
yet no vaccines or drugs are available for prevention or treatment of the virus 
infection. Challenge studies and binding studies using virus-like particles (VLPs) have 
suggested susceptibility to norovirus infection to be associated with secretor status. 
This thesis supports this idea by demonstrating that among 105 Swedish blood donors, 
non-secretors had significantly lower plasma titers of norovirus genogroup (G) II.4 
specific IgG antibodies than secretors (p<0.0001). However, some non-secretors had 
high antibody titers, indicating that secretor independent strains also exist. 
In lack of in vitro cultivation methods, VLPs were used to characterize the glycan 
binding characteristics of different norovirus strains. VLPs from the Chron1 (GII.3) 
and the Dijon (GII.4) strain recognized saliva samples from secretors, but not from 
non-secretors. Using neoglycoproteins, the two VLPs were shown to recognize sialyl 
Lewis x and the structural analogues sialyl diLewis x and sialylated type 2 in addition 
to secretor gene dependent glycans. In contrast, VLPs from the Norwalk (GI.1) strain 
only recognized secretor gene dependent glycans. In inhibition experiments, the sialyl 
Lewis x conjugate could completely block binding of the Chron1 and Dijon VLP to 
saliva samples. 
In search for receptor glycoconjugates, human norovirus VLPs were for the first time 
demonstrated to bind to glycosphingolipids. Using a chromatogram binding assay, 
radiolabeled Norwalk VLPs were shown to recognize both type 1 and type 2 chain 
glycosphingolipids terminated with blood group A and H, but not B epitopes. Quartz 
crystal microbalance with dissipation (QCM-D) monitoring was used to characterize 
VLP binding to glycosphingolipids in supported lipid bilayers. The Norwalk and the 
Dijon VLP bound to bilayers containing H type 1, but not to those containing Lewis a 
glycosphingolipids. In support of multivalency, both VLPs showed a threshold 
concentration of H type 1 below which no binding was observed. 
To conclude, this thesis describes a wide variety of histo-blood group glycoconjugates 
recognized by human noroviruses, suggesting novel approaches for design of 
glycomimetics for norovirus anti-adhesion therapy. 
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ATE N-succinimidyl-3-tributylstannyl benzoate 
BSA bovine serum albumin 
CBA chromatogram binding assay 
CCR5 Chemokine receptor 5 
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1. Introduction 
Infectious gastroenteritis is a common illness (Lopman et al. 2002). Early on, bacteria 
were revealed as a cause of the disease, yet to demonstrate viruses as etiological agents 
was more difficult (Kapikian 2000). The introduction of molecular biology methods for 
viral diagnosis in the 1990s enabled a large proportion of the cases of non-bacterial 
gastroenteritis to be associated with norovirus (Atmar & Estes 2001). 
Today, norovirus is considered to cause about half of all outbreaks of gastroenteritis 
world-wide (Patel et al. 2009). Outbreaks of gastroenteritis in hospitals and other closed 
settings is a large economical problem (Hansen et al. 2007). In developing countries 
norovirus has been estimated to cause up to 200.000 deaths yearly in children of <5 years 
of age (Patel et al. 2008). For reasons not fully understood, the number of reported 
norovirus outbreaks has increased considerably since the emergence of a new virus 
variant in 2002 (Koopmans 2008). Subsequently, large epidemics caused by novel 
norovirus strains have appeared world-wide approximately every other year (Donaldson 
et al. 2008). 
The identification of ABO(H) histo-blood group glycans as potential receptors for 
norovirus, opened a route to design of glycomimetics for anti-adhesion therapy (Le Pendu 
et al. 2006). Currently, no drugs or vaccines for the virus are available. The aim of this 
thesis is to determine the glycan binding characteristics of various norovirus strains to 
facilitate design of attachment inhibitors. 
1.1. Norovirus 
1.1.1. History 
The winter vomiting disease was first described by Zahorsky in 1929 as “an illness 
characterized by the sudden onset of self-limited vomiting and diarrhea that typically 
peaked during the colder months” (Zahorsky 1929). The association of the disease to a 
virus was demonstrated through a series of challenge studies during the 1940s and 1950s 
(Kapikian 2000). These studies excluded bacteria as etiologic agents since the disease 
could be transmitted by fecal samples passed through filters with pore sizes too small to 
allow passage of bacteria. A number of subsequent challenge studies in a series proved 
the agent to multiply within the host, excluding toxins. However, efforts to identify the 
virus using the normal tissue-culture virology approach were not successful. Instead, 
using immunoelectron microscopy, the identification of viruses in stool specimens from 
gastroenteritis patients was achieved in 1972 (Kapikian et al. 1972). The association 
between the virus and the disease was established by demonstrating that antibodies in 
convalescent-phase, but not in prechallenge-phase serum reacted with the virus particles. 
The virus was named Norwalk virus after the specimens used for the identification of the 
virus, derived from an outbreak that occurred in a school in Norwalk, Ohio in 1968 (Adler 
& Zickl 1969). The virus genus was first called Norwalk-like viruses, but the name was 
later changed to “small round structured virus” and finally in 2002 settled to norovirus by 
the international committee on taxonomy of viruses (ICTVdB 2004). The cloning of the 
Norwalk virus genome in 1990 allowed the virus to be characterized as a calicivirus 
(Jiang et al. 1990). 
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1.1.2. Clinical manifestations  
Acute infections 
Norovirus infectious manifestations are characterized by a sudden onset of vomiting and 
diarrhea. Other common symptoms are nausea, abdominal pain, abdominal cramps, 
anorexia, malaise and low-grade fever. Challenge studies with the Norwalk virus have 
demonstrated that the predominant symptom may vary (Atmar & Estes 2006). Thus, some 
individuals only suffer from vomiting whereas others only have diarrhea. Vomiting is 
relatively more common in persons >1 year of age, while children <1 year more often 
develop diarrhea (Patel et al. 2009). The incubation period is usually between 24 and 48 
hours and the symptoms usually last for 12-72 h (Estes et al. 2006). Excretion of 
norovirus was traditionally thought to end within 4 days after infection (Atmar & Estes 
2006). However, studies using more sensitive detection methods (RT-PCR), have 
suggested that virus may be found in stool for more than three weeks after infection 
(Atmar et al. 2008, Rockx et al. 2002). Moreover, in one of these studies norovirus could 
be detected in stools even before the onset of symptoms (Atmar et al. 2008). Norovirus 
infections are generally self-limiting and need no extra treatment than water, glucose and 
electrolyte substitution. Necrotizing enterocolitis has been associated with NoV infection 
in a neonatal intensive care unit (Turcios-Ruiz et al. 2008). Mortality due to dehydration 
associated with norovirus infection has been described for elderly patients (Harris et al. 
2008). 
Chronic infections 
A number of studies have reported chronic norovirus infection in immunocompromised 
patients (Gallimore et al. 2004b, Kaufman et al. 2005, Nilsson et al. 2003, Siebenga et al. 
2008, Westhoff et al. 2009). One of these studies describes a prolonged infection in an 
heart transplant recipient in Sweden (Nilsson et al. 2003). After the initial infection, the 
acute symptoms for this patient turned into diarrhea only. However, neither treatment 
with breast milk nor immunoglobulin, administrated first orally and later intravenously 
reduced the diarrhea or the virus excretion, as determined by RT-PCR and electron 
microscopy. Not even reduction of the immunosuppression (azathioprine and 
cyclosporine) had any effect on the symptoms or on viral excretion. 
Unusual clinical presentations 
A few reports of severe symptoms associated with norovirus infection may be found in 
the literature. One of these describes an outbreak among British soldiers in Afghanistan 
(Brown et al. 2002). In this outbreak, four patients displayed symptoms such as headache, 
neck stiffness, light sensitivity and confusion requiring emergency assistance. 
Furthermore, for one of the patients, disseminated intravascular coagulation was 
observed. In another study norovirus was detected by real-time quantitative RT-PCR in 
stools, serum and cerebrospinal fluid in a 23-month girl with altered consciousness 
suggesting norovirus-associated encephalopathy (Ito et al. 2006). 
Asymptomatic infections 
Early volunteer studies revealed that some individuals were asymptomatically infected 
when challenged with the Norwalk virus (Hutson et al. 2004). These individuals 
developed Norwalk virus-specific antibody response and shed virus, but did not show any 
 3 
symptoms of disease. Such infections have also been identified in outbreaks caused by 
other norovirus strains (Gallimore et al. 2004a, Ozawa et al. 2007). 
1.1.3. Classification 
Norovirus, together with sapovirus represent the human caliciviruses (Fig. 1). The 
prevalence of sapovirus, also causing gastroenteritis, is hard to estimate since few studies 
of the virus have been conducted. However, infections of young children seem more 
frequent than of adults (Hansman et al. 2007). The other two members of the calicivirus 
family, lago- and vesivirus, infect animals and include rabbit hemorrhagic disease virus 
(RHDV) and feline calicivirus (FCV). 
Historically, the classification of noroviruses was based on cross-challenge studies in 
volunteers (Wyatt et al. 1974) and analysis of antisera cross-reactivity by immunoelectron 
microscopy (Lewis et al. 1995). In lack of a cell culture system, the current classification 
is based on sequence similarities in the capsid protein (Zheng et al. 2006). Currently, five 
genogroups (G) are recognized (Fig. 2). The genogroups GI, GII, and GIV contain human 
strains, whereas GIII infect cattle and GV contains murine strains (Scipioni et al. 2008). 
Porcine strains are found in GII and recently a lion (Martella et al. 2007) and a dog 
(Martella et al. 2008) strain have been identified in GIV. The difference in amino acid 
sequence of the major capsid protein is as much as 43% between isolates within the same 
genogroup and up to 61% between isolates from different genogroups. The strains may be 
further classified into genetic clusters within each genogroup. Today 31 such clusters 
have been identified (Fig. 2) (Wang et al. 2005, Zheng et al. 2006). The difference in 
amino acid sequence of the major capsid protein between strains in the same genocluster 
is up to 14% (Zheng et al. 2006). 
1.1.4. Laboratory diagnosis 
Before the introduction of molecular biology methods, norovirus diagnosis was based on 
immunoelectron microscopy. This method was time consuming. Consequently, the impact 
of norovirus was underestimated. The standard assay to diagnose a norovirus infection 
today is RT-PCR using fecal samples (Atmar & Estes 2001, 2006). Because of the 
extensive sequence diversity, no single primer pair can detect all strains of norovirus. 
However, >90% of all strains can be detected using separate primer pairs for GI and GII. 
The time of the analysis can be reduced by using real-time RT-PCR (Atmar & Estes 
2006). 
Calicivirus
Lagovirus
Norovirus
Sapovirus
Vesivirus
Vesicular exanthema of swine virus (VESV)
Feline calicivirus (FCV)
Rabbit hemorrhagic disease virus (RHDV)
European brown hare syndrome virus (EBHSV)
Sapporo virus (SV)
Norwalk virus (NV)
Family                      Genus           Species
 
Figure 1 
The genus and species of the calicivirus family. See also Figure 2 for norovirus heterogeneity. 
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Enzyme-linked immunosorbent assays (ELISAs) for norovirus detection are also available 
(Atmar & Estes 2006). These typically have poor sensitivity (40-60%) but similar 
specificity (94-96%) compared to RT-PCR (Gray et al. 2007, Patel et al. 2009). The low 
sensitivity is associated with the high antigenic diversity of norovirus strains. Because of 
the high specificity ELISAs may be useful for diagnosing norovirus in outbreak 
investigations where several specimens are available (Patel et al. 2009). 
1.1.5. Epidemiology 
Norovirus is considered to cause about half of all outbreaks of gastroenteritis and 75-90% 
of all outbreaks of non-bacterial gastroenteritis in developed countries (Atmar & Estes 
2006, Fankhauser et al. 2002, Lopman et al. 2003). The impact of norovirus in developing 
countries has been less well studied but recent estimations suggest that it is large enough 
to state that norovirus causes about half of all outbreaks of gastroenteritis world-wide 
VA387(Virginia Beach) US ¤
Dijon FRA
HOV (Houston) US
GII.4 Bristol GBR
GII.10 Erfurt DEU
GII.5 Hillingdon GBR
GII.2 Melksham GBR
GII.12 Wortley GBR
GII.1 Hawaii USA
GII.16 Tiffin USA
GII.17 CSE1 USA
Chron01 SWE
GII.3 Toronto CAN
GII.6 Seacrof GBR
GII.13 Faytvil USA
GII.19 QW170 USPorcine
GII.11 918 JPNPorcine
GII.18 QW101 USPorcine
GII.9 VA207 (Virginia Beach) USA
GII.8 Amsterdam NLD
GII.14 M7 USA
GII.7 Leeds GBR
GII.15 J23 USA
GIV.1 Alphatron NLD
GIII.2 CH126 NLDBovine
GIII.1 Jena DEUBovine
GI.7 Winchester GBR
GI.3 DSV USA
GI.8 Boxer USA
GI.5 Musgrove GBR
GI.4 Chiba JPN
GI.2 SOV (Southampton) GBR
GI.1 NV (Norwalk) USA ¤
GI.6 Hesse DEU
GV.1 1 USAMurine
GI
GIII
GIV
GV
GII
Human
Pig
Human
Lion
Dog
Cow
Human
Mouse  
Figure 2 
Phylogenetic analysis of the complete major capsid protein amino acid sequence of the norovirus 
strains studied in this thesis (bold), the suggested type strains for each genocluster (Wang et al. 
2005, Zheng et al. 2006) and strains with the structure of the capsid protein determined (¤). Name 
and country of isolation are given for each strain. For the type strains genoclusters are indicated. 
Host species other than humans are indicated in italic together with the strain name. In addition, 
the host species for each genogroup is indicated. The full length sequence of the major capsid 
proteins were aligned using ClustalW2 with default settings on the European Bioinformatics 
Institute server (Larkin et al. 2007). The tree was constructed from the alignment using the 
Evolutionary Trace server (Trace Suite II, University of Cambridge) (Innis et al. 2000). 
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(Atmar & Estes 2006, Patel et al. 2009, Patel et al. 2008). It has been estimated that 
norovirus cause 23 million infections, 50 000 hospitalizations and 300 deaths per year in 
the USA (Mead et al. 1999). 
The number of norovirus cases identified has clearly increased during the last years. The 
importance of the introduction of detection assays with increased sensitivity for this 
increase is hard to determine (Widdowson et al. 2005). However, the emergence of a new 
GII.4 variant in the winter of 2002 has been well established (Lopman et al. 2004, 
Widdowson et al. 2004). The new variant displaced other strains and caused a large 
epidemic. Subsequently, novel GII.4 subgroups have developed, causing new epidemics 
over the world (Bucardo et al. 2008, Kroneman et al. 2008, Okada et al. 2005, Patel et al. 
2008), including Sweden (Johansen et al. 2008). During these years, GII.4 strains have 
caused more than half of all reported norovirus outbreaks (Donaldson et al. 2008, 
Kroneman et al. 2008, Patel et al. 2008). 
Seasonality 
As the name suggests, the winter vomiting disease is more common during wintertime, 
even though it is diagnosed year-round (Fig. 3).The reason for the seasonality is unclear, 
but it has been postulated that it is due to a combination of climatic conditions that favor 
the survival of the virus and an increased likelihood of person-to-person and food-borne 
transmission caused by social behavior (Lopman et al. 2004). It has been suggested that 
the seasonality is largely caused by GII strains, whereas GI strains are more evenly spread 
over the year (Nordgren et al. 2008). 
Transmission 
Noroviruses are primarily transmitted through the fecal-oral route, usually either by 
consumption of contaminated food or water or by direct person-to person contact (Atmar 
& Estes 2006). The virus is also spread by infectious vomit (Said et al. 2008). Outbreaks 
have been associated with raspberries, oysters, salads, sandwiches and bakery products 
(Bresee et al. 2002). Oysters are particularly interesting vehicles as Norwalk virus-like 
particles (VLPs) have been demonstrated to bind specifically to oyster tissues (Le 
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Figure 3   
Number of norovirus cases reported to the Swedish Institute for Infectious Disease Control from 
the seasons 2003-2009 per week. Data obtained from Hedlund (2009).  
 6 
Guyader et al. 2006). The secondary attack rate in outbreaks may exceed 30%, causing 
large outbreaks, especially in closed settings such as hospitals, retirement centers and 
cruise ships (Atmar & Estes 2006, Said et al. 2008). Together with influenza viruses, 
norovirus has been identified as the most common reason for closure of hospital wards 
(Hansen et al. 2007). Strains belonging to GII.4 are especially common amongst 
outbreaks in closed settings (Said et al. 2008). 
The spread of norovirus is facilitated by the prolonged duration of virus shedding, which 
may last for weeks and for chronically infected patients several years. Transmission 
following recovery from symptomatic infection has been demonstrated (Patterson et al. 
1993). If in addition, some individuals may get asymptomatically infected (section 1.1.2), 
the impact of asymptomatic virus shedding on virus transmission may be assumed to be 
large.  
Norovirus is extremely infectious. Based on challenge studies with the Norwalk virus, the 
probability of infection with a single virus particle has been estimated to be close to 50% 
among genetically susceptible individuals (Teunis et al. 2008). The spread of the virus is 
further facilitated by its high environmental stability. Norovirus seems highly resistant to 
alcohol and quaternary ammonium compounds (Bresee et al. 2002). The suggested 
method for disinfection is cleaning with detergent followed by household bleach at 5000 
ppm (Said et al. 2008).  
1.1.6. Propagation in cell culture 
The study of noroviruses has been hampered by the lack of in vitro cultivation systems. 
The recently discovered murine norovirus grows in cell-culture (section 1.1.9), but despite 
extensive efforts (Duizer et al. 2004) human norovirus has not yet been replicated 
productively in cultured cells. In one study, limited replication of human noroviruses was 
achieved using a 3D organoid model derived from a human intestinal epithelium cell-line 
(Straub et al. 2007). In another study, viral RNA transfected into human hepatoma cells 
(Huh-7) was shown to be replicated and also subsequently released from the cells together 
with viral particles (Guix et al. 2007). The latter study suggests that viral RNA is 
infectious in cultured cells, and that the block to in vitro cultivation occurs at the stage of 
receptor and/or co-receptor binding and/or uncoating. 
1.1.7. Virus structure and genome 
The norovirus genome is a positive-sense single stranded RNA with an approximate 
length of 7.5 kb, organized into 3 open reading frames (ORFs) (Fig. 4). ORF1 encodes a 
non-structural polyprotein, which is cleaved by the viral protease, 3CLpro, into at least six 
proteins (Hardy 2005). Beginning at the N-terminal of the polyprotein these are: p48, 
which has been proposed to interfere with cellular trafficking; the nucleoside 
triphosphatase, NTPase; p22, which has an unknown function but shows some similarity 
to the picornavirus 3A protein involved in membrane localization of replication 
complexes; VPg, which is covalently linked to genomic and subgenomic RNA and 
proposed to interact with translation initiation factors (Chaudhry et al. 2006); 3CLpro, the 
viral protease; and finally RdRp, the RNA-dependent RNA polymerase (Hardy 2005). 
ORF2 encodes the major capsid protein and ORF3 encodes a minor structural protein 
(Glass et al. 2000, Jiang et al. 1992). 
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The virus capsid and virus-like particles 
The lack of success in growing noroviruses in cell culture has greatly impaired the study 
of the biological properties of the virus (Duizer et al. 2004). Therefore, the observation 
that virus-like particles (VLPs) could be formed by expressing the capsid protein in insect 
cells, transfected with a recombinant baculovirus, was of great importance (Jiang et al. 
1992). Furthermore, the VLPs were shown to be morphologically and antigenically 
similar to authentic virions (Green et al. 1993, Jiang et al. 1992). Subsequently, VLPs 
have also been produced in venezuelan equine encephalitis virus replicon vectors in 
mammalian cells (Baric et al. 2002). The three dimensional structure of the Norwalk VLP 
has been determined by X-ray crystallography at a resolution of 3.4 Å  (Prasad et al. 
1999). The virus capsid has a T = 3 icosahedral symmetry, which means that it may be 
modeled from 60 identical equilateral triangles each consisting of 3 copies of the capsid 
protein (Fig. 5). The X-ray structure demonstrated that the major capsid protein folds into 
two domains, the S and P domains. The S domain forms the interior shell of the virus 
capsid, while the P domain forms dimers extending from the shell in arch like structures. 
Subsequent morphogenesis studies have revealed that the S domain is required for 
assembly of the capsid while intermolecular contacts between the dimeric P domains 
increase the stability of the capsid (Bertolotti-Ciarlet et al. 2002). The P domain is further 
divided into the P1 and P2 domains with the latter being the most exterior one (Prasad et 
al. 1999). By expressing only the P domain of the capsid protein, P dimers (Tan et al. 
2004b) and P particles (Tan et al. 2008a, Tan & Jiang 2005b) may be formed. P particles 
and P domains show similar binding patterns compared to the corresponding VLPs and 
may, in contrast to VLPs, be produced in E. coli or yeast. Interestingly, a large amount of 
soluble P domains are found in stool specimens of norovirus infected patients, even 
though it is not known whether these form P particles or not (Hardy et al. 1995). 
Cryo-EM studies of VLPs from the Grimsby strain (GII.4) have suggested that the overall 
structure is similar to the structure of the Norwalk virus (Chen et al. 2004). The identified 
differences were mainly located to the P2 domain and the relative orientation between the 
S and P domains. However, a recent cryo-electron microscopy study of the murine 
norovirus has suggested that the P domains in that strain is rotated as much as 40 degrees 
compared to the structure of the Norwalk virus (Katpally et al. 2008). 
In addition to the major capsid protein, one or two copies of the minor capsid protein can 
be found in each virion (Hardy 2005). The minor capsid protein is also included in some 
VLPs. The function of this protein is unknown, but it has been proposed to function in 
RNA genome packaging (Glass et al. 2000) and for increasing the expression and the 
stability of the major capsid protein (Bertolotti-Ciarlet et al. 2003). 
1.1.8. Pathogenesis 
The target cell for human norovirus has not been unequivocally identified, but it is 
assumed that the virus replicates in the upper intestinal tract. Thus, biopsies of the 
5' (A) 3'np48      NTPase  p22  VPg  3CLpro       RdRp VP1 VP2
ORF1 ORF2 ORF3
 
Figure 4 
Norovirus genome organization (Hardy 2005). 
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jejunum from volunteers challenged with the Norwalk (GI.1) or Hawaii (GII.1) virus have 
been demonstrated to exhibit histopathologic lesions (Agus et al. 1973, Schreiber et al. 
1973, 1974). These studies revealed reversible broadening and blunting of the jejunal villi 
whereas the mucosa remained histologically intact. Also infiltration with mononuclear 
cells in the epithelium and cytoplasmic vacuolization was observed. Furthermore, the 
studies showed that infection was accompanied by transient fat and D-xylose 
malabsorption. Jejunal lesions have also been identified in individuals who did not 
develop symptomatic disease after virus challenge (Schreiber et al. 1973, 1974). Studies 
of biopsies from a more recent challenge study have confirmed and extended the results 
from the old challenge studies (Troeger et al. 2008). In the latter study, the infiltrating 
mononuclear cells were identified as CD8+ lymphocytes belonging to a unique T-cell 
population interspersed between epithelial cells both in the small and the large intestine. 
The study also suggested that these T-cells may be involved in the morphological 
alterations of the villi induced by the virus.  
So far, it has not been possible to visualize virus particles in biopsies from norovirus 
challenge studies. However, a study of Norwalk VLPs binding to tissue sections of the 
gastroduodenal junction demonstrated binding mainly at the villi level and weaker 
binding at the crypt level (Marionneau et al. 2002). 
1.1.9. Animal models 
Murine norovirus 
The discovery of the murine norovirus (Karst et al. 2003) and the subsequent propagation 
of the virus in cell culture (Wobus et al. 2004) were major breakthroughs for the 
norovirus field (Scipioni et al. 2008, Wobus et al. 2006). The murine norovirus was 
identified in immunocompromised mice lacking the recombination-activating gene 2 
(RAG2) as well as signal transducer and activator of transcription 1 (STAT1) 
(RAG2/STAT1-/-). The animals sporadically succumbed to a systemic disease (Karst et al. 
2003). However, subsequent studies have demonstrated that around 30% of mice in 
research facilities throughout the United States, Canada and Europe have antibodies 
against murine norovirus in serum, suggesting it is possibly the most prevalent of all 
endemic viruses in research mice (Henderson 2008, Pritchett-Corning et al. 2009). At 
least one article describing a direct influence of murine norovirus on research 
investigations has been published (Lencioni et al. 2008).  
                 
Figure 5 
Structure of the Norwalk virus capsids. The 
diameter of the capsid is approximately 38 
nm. The coordinates were adopted from 
Prasad et al. (1999) and the image was 
constructed using the Chimera package 
(Pettersen et al. 2004). 
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Immunocompromised mice infected with murine norovirus develop a systemic disease 
with signs of encephalitis, vasculitis in cerebral vessels, pneumonia and hepatitis whereas 
infection in wild-type mice seems to be asymptomatic (Henderson 2008, Wobus et al. 
2006). An interesting parallel is the severe human norovirus infections observed in 
immunocompromised patients (section 1.1.2). Studies in wild type mice have shown that 
the infection is established in the proximal small intestine and that the virus subsequently 
spreads to other organs such as the liver, lungs, lymph nodes and spleen (Henderson 
2008). The virus is shed in stool, resulting in fecal-oral transmission (Manuel et al. 2008). 
In cell culture, murine norovirus has a tropism for cells of the hematopoietic lineage, 
specifically macrophages and dendritic cells (Wobus et al. 2004). 
Human norovirus in gnotobic pigs and calves 
Porcine noroviruses form the distinct genoclusters GII.11, GII.18 and GII.19. So far, no 
human noroviruses have been classified into these clusters (Scipioni et al. 2008). 
However, recent studies have demonstrated that gnotobic pigs can be experimentally 
infected with human GII.4 strains (Cheetham et al. 2006, Souza et al. 2007). In the first of 
these studies, 74% of the inoculated pigs developed mild diarrhea, even though only 44% 
secreted detectable amounts of viral RNA in feces (Cheetham et al. 2006). In the second 
study, it was demonstrated that GII.4 norovirus induced a Th1 like immune response 
(Souza et al. 2007). Such a response was recently demonstrated also for gnotobiotic 
calves infected with the same virus strain (Souza et al. 2008). Finally, VLP binding 
studies on paraffin-embedded intestinal tissues from gnotobiotic pigs have suggested that 
the virus adheres to carbohydrate structures related to the glycans suggested as receptors 
for human norovirus (Cheetham et al. 2007). 
Zoonosis 
The demonstration of cross-infection of human norovirus in pigs and calves raises 
concerns about risk for zoonosis. Co-infections of animal and human norovirus possess a 
risk for genetic mixing as recombination seems to be common for noroviruses (Bull et al. 
2007). In this context, a recent study reporting detection of GII.4 strains in livestock pig 
stool samples and also in a retail meat sample, is worrying (Mattison et al. 2007).  
1.1.10. Immunity 
Most of the information regarding immunity to norovirus infections has been obtained in 
challenge studies. The interpretation of the early studies is complicated by the absence of 
information regarding secretor status. Furthermore, the viral dose administered in most 
studies must be considered extremely high, as the infectivity of a single Norwalk virus 
particle recently has been estimated to be close to 50% (Teunis et al. 2008). Nevertheless, 
early challenge studies have demonstrated the existence of short term immunity (Dolin et 
al. 1972, Parrino et al. 1977, Wyatt et al. 1974). Furthermore, a cross-challenge study 
using the Norwalk (GI.1) and Hawaii (GII.1) strains suggested the immunity to be strain 
or genogroup specific (Wyatt et al. 1974). This was illustrated by the finding that 
volunteers, who fell ill following a virus challenge were usually shown to be protected 
when being re-challenged with the same virus strain 6-14 weeks later. However, when re-
challenged with the other strain they fell ill again.  
The results from the challenge studies regarding long-term immunity are conflicting 
(Donaldson et al. 2008). One study demonstrated that when volunteers who initially fell 
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ill were re-challenged with the same inoculum of Norwalk virus after 2-4 years they 
became symptomatically infected again (Parrino et al. 1977). In a more recent challenge 
study 44% of the genetically susceptible individuals were not infected, indicating the 
presence of long-term immunity (Lindesmith et al. 2003). Furthermore, early longitudinal 
studies suggested that serum antibody titers were associated with protection of children 
against norovirus infection (Black et al. 1982, Ryder et al. 1985). However, pre-challenge 
antibody titers could not be correlated to susceptibility in challenge studies (Johnson et al. 
1990). 
Antibody cross-reactivity 
A number of studies have demonstrated antibody cross-reactivity between different 
strains of norovirus, especially within each genogroup (Hale et al. 1998, Lindesmith et al. 
2005, Rockx et al. 2005a, Rockx et al. 2005b). The cross-reactivity of blocking antibodies 
seem to be more restricted (Harrington et al. 2002b, Rockx et al. 2005a, Rockx et al. 
2005b). 
Until recently, the information regarding antibody cross-reactivity within genogroups was 
limited. However, in a recent study VLPs representing different GII.4 subgroups that have 
caused time-ordered global epidemics, were constructed (Lindesmith et al. 2008). 
Thereby the antigenic evolution of this genocluster could be studied (Cannon et al. 2009, 
Lindesmith et al. 2008). By measuring titers of IgG antibodies towards the different VLPs 
in antisera from mice immunized by each VLP, serological differences between the VLPs 
could be identified (Lindesmith et al. 2008). Similarly, differences could be identified 
using pre- and post-epidemic human anti-sera (Cannon et al. 2009, Lindesmith et al. 
2008). Importantly, pre-epidemic anti-sera were shown to poorly recognize post-epidemic 
VLPs (Cannon et al. 2009, Lindesmith et al. 2008).  
These two studies suggest that GII.4 norovirus evolves by so called epochal evolution 
(Donaldson et al. 2008). Other studies have proposed a similar evolutionary process based 
on bioinformatics analysis (Allen et al. 2008, Siebenga et al. 2007). Epochal evolution 
means that periods of stasis (epochs), under which the genetic diversity grows, are 
followed by sudden changes in phenotype and emergence of novel epidemic strains. Only 
a subset of the genetic variation observed accounts for the change in fitness (Donaldson et 
al. 2008). An epochal evolution has been suggested also for the influenza virus (van 
Nimwegen 2006). For this virus the process of antigenic drift is even faster, as it seems to 
evade herd immunity on a yearly basis. 
Chronic human norovirus infections represent in vivo models to study the effects and 
localization of viral mutations over time. From the Swedish patient with a chronic GII.3 
infection described in section 1.1.2 viral sequences were obtained once a month during 
one year. Eleven amino acid mutations accumulated in the major capsid protein could be 
detected (Nilsson et al. 2003). Notably, 8 of these mutations occurred in the outermost 
domain (P2) of the capsid protein, indicating an immune driven selection. Later, 3 of the 
11 amino acids were identified to achieve accumulated mutations in a similar study of 
three other patients with chronic GII.3 infections (Siebenga et al. 2008). In a recent study, 
the virus in the Swedish patient was demonstrated to evolve as a quasispecies population. 
Capsid sequences isolated at the same time point tended to cluster together in a 
phylogenetic analysis (Carlsson et al. 2009b). The glycan binding pattern of a VLP 
constructed from the first viral isolate from this patient is described in Paper II.  
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1.2. Glycobiology 
Glycans are, together with nucleic acids, proteins and lipids, the fundamental 
macromolecules of all living cells (Marth 2008). In comparison to nucleic acids and 
proteins, glycans have an enormous information coding capacity per monomeric unit in 
the polymer. This is mainly because glycans, in contrast to the other two polymer classes, 
have a variability of linkage positions, anomeric configuration and the ability to form 
branched structures (Gabius 2008). These variabilities make glycans ideal for high-
density information storage. This stored information is mainly decoded by glycan binding 
proteins, e.g. glycosyl-transferases, -hydrolases and lectins. 
Glycan-protein interactions are involved in a wide range of biological functions. These 
include protein maturation and turnover, cell adhesion and trafficking as well as receptor 
binding and activation (Marth & Grewal 2008). The extensive use of glycans as small 
ligands for proteins is probably not explained solely by their coding capacity. Of 
relevance is probably also the fact that glycans have few energetically favoured 
conformations. Even though carbohydrates are often considered to be flexible molecules, 
they are generally more rigid than peptides of the same weight. Thus, it has been proposed 
that the entropic cost of locking a ligand in a protein binding pocket is lower for a glycan 
compared to a similar sized peptide (Gabius 2008). Another important property of 
protein-carbohydrate interactions is the ability to fine-tune interactions by multivalency 
(section 1.3.4). 
1.2.1. Glycan biosynthesis 
In contrast to proteins, glycans are secondary gene products. Thus, glycans are not 
directly encoded by the genome, but instead produced by the sequential action of 
glycosyltransferases and other glycan-processing enzymes (Ohtsubo & Marth 2006). 
Consequently, glycan synthesis is not template driven, but instead, in each cell, 
determined by the availability and specificity of the enzymes involved and the 
competition between them. Also the availability of substrates and acceptor structures for 
the different enzymes affects the biosynthesis. The regulation of the glycan-processing 
enzymes is complex (Murrell et al. 2004) and, in addition to cell and tissue specific 
expression, at least some of them exist in different splice forms (Grahn et al. 2002, Grahn 
& Larson 2001, Russo et al. 1990). Glycosyltransferases may be found both as membrane 
bound and as soluble proteins (Hart et al. 2007). Furthermore, chaperones and other 
activator proteins are essential for activity and correct localization of some 
glycosyltransferases (Ju & Cummings 2002, Wu et al. 2004). 
1.2.2. Glycoconjugates 
Glycans may occur as free saccharides but are usually covalently linked to either proteins 
or lipids. The protein or lipid in such glycoconjugates is denoted the aglycone and may be 
directly involved in interactions with proteins together with the glycan (Cummings & 
Esko 2008). In addition the aglycone may influence protein interactions indirectly by 
affecting the conformation or the availability of the glycan (Lingwood 1996). 
Glycoproteins 
In glycoproteins, the glycans are usually linked either to the side-chain nitrogen of an 
aspargine (N-linked) or to the side-chain oxygen of a serine or threonine residue 
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(O-linked) (Brockhausen et al. 2008, Stanley et al. 2008). Of these classes, N-linked 
glycans are the most studied because of their essential functions in protein folding and 
quality control in the secretory pathway. Aspargines linked to N-glycans are commonly 
found in the consensus sequence Asn-X-Ser/Thr. O-linked glycans are typically found 
densely packed in mucin domains, where they contribute to the hydration of the mucus as 
well as to the protection of the underlying tissue. In analogy with N-glycans, O-glycans 
may function in signaling, as exemplified by the O-fucose and O-glucose linked glycans 
on the Notch receptor (Acar et al. 2008, Stahl et al. 2008). Glycans contribute to the 
structural properties of glycoproteins and do in many cases protect the polypeptide 
backbone from proteases. Many receptors on the cell surface are glycosylated. The 
glycans are important for the localization of these proteins. In addition, the halftime of 
circulating serum glycoproteins depends on the glycans since receptors in the liver 
internalize glycoproteins with terminal Gal or GalNAc residues (Grewal et al. 2008).  
Proteoglycans 
Proteoglycans are a special group of glycoproteins carrying long repetitive linear 
polysaccharides linked to serine side chains. The polysaccharides may constitute up to 
95% of the weight of proteoglycans and thus dominate the chemical properties of the 
conjugate. Proteoglycans are important components of the extracellular matrix and 
provide a hydrated gel resistant to compressive force. Further, proteoglycans are 
important in many biological signaling processes as co-receptors for a number of 
cytokines, chemokines and growth factors (Esko et al. 2008). 
Glycosphingolipids 
Glycosphingolipids (GSLs) are glycolipids based on ceramide (Fig. 6). The ceramide 
component consists of a fatty acid in amide linkage to the amino alcohol sphingosine. The 
length and the number of double bonds of both the sphingosine and the fatty acid may 
vary. Despite these variations, GSLs are usually classified based on their glycans. The 
species-, tissue- and cell-specific distribution suggests that GSLs play important roles. 
Accordingly, mice lacking all of the complex GSLs, as a result of a knockout of the 
glucosylceramide synthase, die as embryos (Yamashita et al. 1999). Mice lacking more 
distal glycosyltransferases show milder phenotypes (Degroote et al. 2004). On the cellular 
level the GSLs seem to play important roles for the organization of the plasma membrane 
and appear to be important also for the sorting of proteins. GSLs associate with 
cholesterol, sphingomyelin, and other sphingolipids to form micro domains called lipid-
rafts. Studies suggest that GSLs are not essential for the formation of these detergent 
resistant domains, but rather vital for specific functions fulfilled by the domains 
NH
O
OH
O
O
O
O
O
O
Sphingosine
Fatty acid
 
Figure 6 
Structure of a glucosylceramide. The ceramide shown consists of sphingosine (dihydroxy 18:1) 
and stearic (18:0) fatty acid. 
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(Degroote et al. 2004). It has been shown that GSLs are involved in cell signaling 
interactions with lectins (Kopitz et al. 1998, Schnaar et al. 1998). Cell signaling also 
involves GSL-GSL interactions (Hakomori 2004). Moreover, GSLs can modulate 
signaling by interaction with key transmembrane receptors (Degroote et al. 2004). 
1.2.3. The ABO(H) and Lewis histo-blood group systems 
The ABO blood group system was discovered by Karl Landsteiner over a century ago and 
the carbohydrate basis of the antigens involved was described by Morgan half a century 
later (Morgan 1950). In the ABO system, individuals are classified by blood group A, B, 
AB or O (neither A nor B) depending on which antigen(s) are displayed on their 
erythrocytes. Since natural IgM antibodies are produced against antigens not present 
(non-self), blood transfusions can only be performed in the directions illustrated in Figure 
7. The ABO antigens are also widely distributed in other tissues and thus these antigens 
are often referred to as histo-blood group antigens (Clausen & Hakomori 1989).  
The ABO blood group system is closely related to the Lewis system as the antigens of 
both systems may be present on the same carbohydrate chains and overlap structurally as 
well as biosynthetically. The antigens are mainly found on four different carbohydrate 
chains, designated type 1-4 (Table 1). 
Biosynthesis 
The biosynthesis of the ABO(H) and Lewis histo-blood group structures is illustrated in 
Figure 8. The principles for the synthesis of the A, B and H antigens are applicable for all 
chain types, whereas the synthesis of the Lewis antigens, containing ?1,3- or ?1,4-linked 
fucose, is restricted to the type 1 and 2 chains. 
The H antigens 
The biosynthesis of the ABO antigens starts with the addition of an ?1,2-linked fucose to 
the terminal galactose on either of the 4 precursor chains, to form the H epitope (Fig. 8). 
The human genome encodes two functional ?1,2-fucosyltransferases, denoted FucT-I and 
O
A B
AB  
 
Table 1 Carbohydrate chains carrying ABO(H) and Lewis histo-blood groups (Clausen et al. 
1985b, Marionneau et al. 2001, Ravn & Dabelsteen 2000)  
Name Structure Found on 
Type 1 Gal?1,3GlcNAc?1-R N-,O-glycoproteins, GSLs of the lactoseries 
Type 2 Gal?1,4GlcNAc?1-R N-,O-glycoproteins, GSLs of the neolactoseries 
Type 3 Gal?1,3GalNAc?1-R O-glycoproteins (core 1), GSLs as elongated 
blood group A series 
Type 4 Gal?1,3GalNAc?1-R GSLs of globo and ganglioseries 
GSLs = glycosphingolipids 
Figure 7 
Blood transfusion may be performed across the ABO blood groups 
in the directions indicated by the arrows. Blood group O 
individuals are universal donors whereas blood group AB 
individuals are universal receivers. This chart is often referred to 
as the Landsteiner rule. 
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FucT-II and encoded by the FUT1 and FUT2 genes, respectively (Kelly et al. 1995, Rajan 
et al. 1989). These enzymes differ in their acceptor specificities and expression profiles 
and both of them are polymorphic in the human population. Historically, FUT2 was 
assumed to be a regulatory gene controlling the expression of FUT1 in secretions. It was 
thus controversial when Oriol and co-workers in 1981 suggested (Oriol et al. 1981) and 
later demonstrated (Le Pendu et al. 1985) the existence of two distinct human 
?1,2-fucosyltransferases. 
The distribution of the H antigens in human tissues in relation to expression of FUT1 and 
FUT2 has been reviewed (Mollicone et al. 1995, Oriol et al. 1986, Ravn & Dabelsteen 
2000). The FucT-I is considered to be active exclusively, or at least predominantly, 
towards the type 2 chain whereas the type 1 and type 3 chains are the typical acceptors for 
FucT-II. However, FucT-II is active also towards the type 2 chain (Ravn & Dabelsteen 
2000). A recent study of breast cancer stem cells suggests that both FucT-I and FucT-II 
may synthesize H type 4 (Chang et al. 2008). Ravn and Dabelsteen suggest that the 
degree of cell differentiation affects the expression of FucT-I and FucT-II (Ravn & 
Dabelsteen 2000). Undifferentiated cells tend to express FUT1, whereas more 
differentiated cells tend to express FUT2. The expression of FUT1 in bone marrow 
erythropoietic cells is clearly analogous with this. A supporting observation is that the 
?1,2-fucosylation of type 2 chain structures in the mucus cells of the pyloric and 
Brunner's glands is independent of FUT2 (Mollicone et al. 1985).  
As the H epitope is the acceptor for the blood group A and B transferases, the 
biosynthesis of the A and B antigens requires the expression of a functional 
?1,2-fucosyltransferase. Thus, the biosynthesis of the A and B epitopes on the type 1 
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Figure 8 
Biosynthetic pathways of the ABO(H) and Lewis antigens on the type 1/2 (A) and 3/4 (B) chains. 
Antigen names (bold), glycosyltransferases (italic) and linkages of the different chains are, when 
differing between the chains in each figure, separated by a diagonal in the format indicated by 
the antigen names.  
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chain is strictly dependent on the expression of a functional FUT2 gene, whereas the 
biosynthesis of the same epitopes on the type 2 chain may be dependent on either FUT1 
or FUT2. However, since these transferases show different expression profiles, the 
expression of H antigens on erythrocytes and vascular endothelium is dependent on 
FUT1, whereas the expression of the antigens on most epithelial cells and in mucosal 
secretions, is dependent on FUT2 (Mollicone et al. 1995, Ravn & Dabelsteen 2000). 
About 20% of the Caucasian population have two non-functional FUT2 alleles and 
consequently do not express any ABH blood group antigens on epithelial cells or in 
mucosal secretions. These individuals cannot have their ABO blood group determined 
from saliva and are denoted non-secretors (sese). In contrast, individuals with at least one 
functional FUT2 allele are denoted secretors (Sese or SeSe). The most common and 
completely dominating (>99%) inactivating mutation of FUT2 in the Caucasian 
population is G428A, which introduces a premature stop codon in the gene (Kelly et al. 
1995). The mutation A385T causes a weakened enzyme activity and the so called weak 
secretor phenotype common in Asia (Henry et al. 1996b, a, Yu et al. 1995). An additional 
50 inactivated an non-inactivated human FUT2 alleles are listed in the blood group 
antigen gene mutation database (dbRBC) (Blumenfeld & Patnaik 2004). 
Inactivating mutations have been found also in FUT1, even though these are much more 
rare than the mutations causing the non-secretor genotype (Koda et al. 2001). Many of the 
FUT1 mutations are linked to inactivating mutations in FUT2, which is located close to 
FUT1 on chromosome 19 (Fernandez-Mateos et al. 1998, Koda et al. 1997). Thus, 
homozygote carriers of inactivating mutations in FUT1 often lack both FucT-I and 
FucT-II activity and are consequently devoid of all A, B and H antigens. This phenotype 
is denoted Bombay, after the place where it was first identified (Bhende et al. 1952). The 
mutation causing the original Bombay phenotype was T725G in FUT1, linked to a 
deletion mutation in FUT2 (Fernandez-Mateos et al. 1998, Koda et al. 1997). 
Subsequently, other mutations causing the Bombay phenotype have been identified (Koda 
et al. 2001). Estimations suggest 1 in a million Europeans and 1 in 10 000 of Indian 
ancestry to be Bombay individuals (Blumenfeld & Patnaik 2004). Individuals with 
inactivating mutations in FUT1, but a functional FUT2 gene are denoted to be of para-
Bombay phenotype (Koda et al. 2001). 
The A and B antigens 
The glycosyltransferases encoded by the ABO gene are responsible for the addition of the 
terminal ?1,3GalNAc/Gal resulting in the histo-blood group A and B epitopes (Fig 8). 
Blood group A individuals have at least one functional ?1,3-GalNAc transferase (A) 
allele, whereas blood group B individuals have at least one functional ?1,3-Gal 
transferase (B) allele. Blood group AB individuals have one A and one B allele, but may 
in rare cases instead carry a cis-AB allele with both ?1,3GalNAc and ?1,3Gal transferase 
activity (Yazer et al. 2006). Blood group O individuals are homozygous for alleles coding 
for proteins lacking enzymatic activity. The cloning of the ABO alleles showed that the 
typical A and B enzymes differ in only 4 out of 354 amino acids (Yamamoto et al. 1990). 
Subsequent studies have revealed that the ABO gene is highly polymorphic. More than 
160 alleles are now described (Blumenfeld & Patnaik 2004). The most common 
subgroups are the A1 and A2 phenotypes constituting about 80% and 20% of the blood 
group A individuals, respectively. Individuals in the A2 group have a less efficient 
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enzyme than those in the A1 group. The most common A2 allele is characterized by a 
single base deletion mutation creating an enzyme with 21 extra amino acids (Yamamoto 
et al. 1992). Because of the lower enzyme activity, erythrocytes of A2 individuals display 
a lower number of A epitopes and a larger number of H epitopes compared to 
erythrocytes of A1 individuals (Svensson et al. 2009). However, qualitative differences 
between the groups also exist. Both the A type 3 GSL 
(GalNAc?3(Fuc?2)Gal?3GalNAc?3(Fuc?2)Gal?4GlcNAc?3Gal?4Glc?Cer) (Clausen 
et al. 1985b) and the A type 4 (Globo A) GSL 
(GalNAc?3(Fuc?2)Gal?3GalNAc?3Gal?4Gal?4Glc?Cer ) (Clausen et al. 1984) have 
been reported to be restricted to A1 individuals. However, recent experiments have 
suggested that when compensating for the lower amount of A epitopes on GSL extracts 
from A2 erythrocytes, only the A type 4 structure remains unique for A1 individuals 
(Svensson et al. 2009). 
The Lewis antigens 
The Lewis blood group system refers to the presence - or absence - of an ?1,3- or 
?1,4-linked fucose on the subterminal GlcNAc on the type 1 and type 2 chains, in 
combination with the presence or absence of the H epitope, on the same glycan.  
The addition of an ?1,4-linked fucose to the type 1 chain precursor forms the Lewis a 
(Lea) structure, whereas the addition of a similar fucose to the H type 1 structure forms the 
Lewis b (Leb) structure (Fig. 8). In a similar manner the A type 1 and B type 1 structures 
can be transformed into ALeb and BLeb, respectively. The fucosyltransferase catalyzing 
all these reactions is encoded by the Lewis FUT3 gene. Also the gene product of FUT5 
has been reported to have activity for the type 1 chain but since individuals with 
inactivating mutations in FUT3 essentially lack Lea and Leb structures, the FUT3 gene 
product is considered the main enzyme responsible for these differences (Marionneau et 
al. 2001). Homozygote carriers of inactive FUT3 alleles are denoted Lewis negative (lele) 
and constitute about 5% of the Caucasian population (Mollison et al. 1993). The most 
common inactivating mutations in FUT3 are T202C (Elmgren et al. 1997), G508A (Koda 
et al. 1993, Nishihara et al. 1994) and T1067A (Mollicone et al. 1994). Antibodies 
towards Lea and Leb are routinely used to phenotype for secretor status, as the expression 
of Leb, but not Lea, requires a functional FUT2 gene. The phenotyping is generally 
performed on erythrocytes, even though these cells mainly display type 2 chain structures. 
The small amount of type 1 chain structures found on erythrocytes is associated with 
GSLs being adsorbed from plasma lipoproteins (Marcus & Cass 1969). Notably, the 
secretor status of Lewis negative individuals may not be determined using antibodies 
towards Lea and Leb, as those individuals do not express any of the antigens. Lewis 
positive secretors do not express detectable amounts of Lea on erythrocytes. However, 
Lewis positive weak secretors display both Lea and Leb on erythrocytes (Henry et al. 
1990). 
The type 2 chain isomers of Lea and Leb are denoted Lex and Ley respectively (Fig. 8). 
The difucosylated blood group A and B antigens, ALey and BLey also exist. In contrast to 
the ?1,4-fucose of the type 1 chain Lewis structures, a number of different 
fucosyltransferases may catalyze the addition of the ?1,3-fucose, characterizing the type 2 
chain Lewis structures (Marionneau et al. 2001).  
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Sialylated and sulfated antigens 
The type 1 and type 2 precursors may be sialylated by ?2,3-sialyltransferases to form 
sialylated type 1 and 2, respectively. These structures may be acceptors for 
?1,3/4-fucosyltransferases giving sialyl Lewis a (SLea) and sialyl Lewis x (SLex). In 
analogy with Lea and Lex, the synthesis of SLea requires a functional FUT3 gene, whereas 
a number of ?1,3-fucosyltransferases may catalyze the formation of SLex (Marionneau et 
al. 2001). Consequently, the lack of expression of SLex is very uncommon, suggesting an 
important function for the structure. The biosynthesis of SLex is illustrated in Figure 9. 
The Lewis structures may also be modified by sulfation. The most common sulfate 
modifications are attached to carbon 3 or 6 of the terminal Gal residue or to carbon 6 of 
the sub-terminal GlcNAc residue. Examples of sulfated Lewis antigens are 3’-sulfo-Lea, 
3’-sulfo-Lex, 6-sulfo-SLex, 6’-sulfo-SLex and 6,6’-bissulfo-SLex (Stanley & Cummings 
2008).  
Functions of the ABO(H) and Lewis histo-blood groups systems 
Even though the structural basis of the ABO(H) histo blood group glycans has been 
known for a long time the functional role of the system has remained unclear (Greenwell 
1997). However, for some of the less polymorphic structures, specific functions have been 
demonstrated. The blood group glycan with the most thoroughly characterized function is 
SLex. 
Sialyl Lewis x 
SLex is the minimal common ligand for the E-, P- and L-selectins (Lowe 2003). These are 
cell adhesion molecules with important functions for lymphocyte homing and leukocyte 
recruitment to sites of inflammation. In addition to SLex, the E-selectin recognizes SLea 
and VIM-2 (Neu5Ac?3Gal?4GlcNAc?3Gal?4(Fuc?3)GlcNAc?-R) (Lowe 2003) as well 
as heparan sulfate (Varki 2007). For P- and L-selectin, the binding to SLex also involves 
adjacent sulfate groups. Thus, L-selectin shows optimal binding to 6-sulfo-SLex, whereas 
high affinity binding of P-selectin to the P-selectin glycoprotein ligand 1 (PSGL-1) 
requires the presence of specific sulfated tyrosine residues. The importance of SLex as a 
selectin ligand has been demonstrated in transgenic mice lacking various 
glycosyltransferases involved in SLex biosynthesis (Lowe 2003). In these studies 
FucT-VII was identified as the major fucosyltransferase involved in the biosynthesis of 
the glycans responsible for selectin binding. However, the phenotype was more severe in 
the double knockout mice, lacking both FUT4 and FUT7. When it comes to humans, the 
situation is quantatively different. Neutrophils from an individual homozygous for the 
rare inactivating mutation G329A in FUT7 show normal E- and P-selectin binding 
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Figure 9 
The biosynthetic pathway for sialyl Lewis x. Names of antigens are in bold and 
glycosyltransferase genes in italic. 
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activities, despite the lack of SLex expression (Bengtson et al. 2001, Bengtson et al. 
2002). An increase in expression of VIM-2, caused by an upregulation of FUT4, was 
suggested to be responsible for the maintained selectin binding. 
The ABO(H) histo blood group system 
One theory about the function of the ABO(H) histo-blood group system, is that the 
diversity provides resistance to pathogens on the population level. This theory was 
proposed more than 50 years ago (Haldene 1949) and has later been extended (Gagneux 
& Varki 1999). The theory states that a pathogen, using a specific glycan as receptor, 
cannot completely eliminate a population if some individuals lack that specific glycan. 
The diversity in blood group distribution between different populations would thereby 
reflect different histories of infectious diseases. A second selection pressure comes from 
viruses. As they exploit the glycosylation machinery of the host cell, viruses would be 
expected to incorporate histo-blood group glycans during the propagation. Individuals 
with antibodies towards the incorporated glycans would be protected against infection 
with that specific virus as the antibodies would cause complement mediated lysis of the 
virus. The concept has been experimentally evaluated for membrane viruses. These may 
carry blood group glycans not only on viral proteins but also on host proteins and GSLs, 
incorporated into the viral membrane. Cell culture studies have shown that HIV (Neil et 
al. 2005), measles virus (Preece et al. 2002) and SARS (severe acute respiratory 
syndrome) coronavirus (Guillon et al. 2008) may carry ABO blood group structures. The 
selection pressure caused by viral incorporation of blood group antigens suggests blood 
group O individuals to be underrepresented among infected individuals. Epidemiological 
evidence for protection of blood group O individuals in viral outbreaks has been scarce. 
One study of a hospital outbreak of SARS coronavirus, however, reported blood group O 
individuals to have very low odds of infection compared to non-O individuals (Cheng et 
al. 2005, Guillon et al. 2008). 
Experimental proof for the theory is hard to achieve as the diversity seen today reflects a 
long evolutionary process and many of the pathogens involved are not longer present. The 
introduction of the RHDV in new rabbit populations may however provide opportunities 
to study an ongoing evolution of glycan expression. RHDV causes a lethal systemic 
infection and seems to use H type 2 as receptor (Ruvoen-Clouet et al. 2000). Studies of 
buccal epithelial cells from wild rabbits have demonstrated that rabbits with an H type 
2-negative phenotype occur more frequently in areas with a high impact of RHDV 
(Guillon et al. 2009). 
1.3. Receptors and attachment factors 
To infect a cell, a virus must first adhere to it (Helenius 2007, Smith & Helenius 2004). 
Whereas viruses are bound only by the attachment factors, the receptors additionally 
promote the entry of the virus into the cell. Many viruses use more than one receptor 
(Helenius 2007).  
Receptors may promote viral entry through several distinct mechanisms (Helenius 2007). 
Firstly, receptors may induce conformational changes in the virus capsid thus allowing 
further interactions. Secondly, they may transmit signals through the plasma membrane 
that lead to viral uptake. Finally, receptors may guide the virus into various endocytic 
pathways. In practise, the distinction between attachment factors and receptors is 
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complicated. The importance of attachment factors for the viral infection should not be 
underestimated. The concentration of virus particles at the cell surface facilitated by 
attachment factors may be crucial for the subsequent receptor interactions. A large 
number of virus receptors have been identified in different molecular families. Among the 
most represented families are the IgG superfamily of transmembrane proteins, integrins 
and glycoconjugates (Helenius 2007).  
1.3.1. Glycoconjugates 
A large number of viruses interact with glycans (Karlsson 1995, Marsh & Helenius 2006, 
Olofsson & Bergstrom 2005). Interestingly, most of these glycans are negatively charged, 
including sulfated glycosaminoglycans and sialylated glycans. The reason for this charge 
preference is unclear, but few exceptions seem to exist (Olofsson & Bergstrom 2005).  
Proteoglycans 
Numerous viruses interact with sulfated proteoglycans (Olofsson & Bergstrom 2005). 
These molecules also interact with a large number of ligands for various cell surface 
receptors, and thus concentrate these ligands at the cell surface. By this process, 
proteoglycans are important for the formation of many morphogen gradients (Lander 
2007). In a similar manner, for most viruses proteoglycans have been described as 
attachment factors rather than receptors.  
Glycoproteins and glycosphingolipids 
A large number of viruses interact with sialic acids, localized to either GSLs or to 
glycoproteins. Probably, the most known sialic acid binding virus is the influenza A virus 
(Esko & Sharon 2008). Human influenza A virus has a preference for sialic acid linked in 
?2,6-linkage whereas avian influenza A has a preference for sialic acid linked in a 
?2,3-linkage. This difference in binding specificity explains, to a large extent, the host 
tropism for these viruses (section 1.3.2). Despite years of studies, a specific glycoprotein 
or GSL responsible for the entry of influenza virus has not been identified. This illustrates 
the complexity of the entry mechanism. In fact, for most viruses shown to use glycans as 
receptors no specific glycoconjugate receptors has been described. A few examples of 
glycoconjugate receptors will be given below. 
Glycoproteins 
The glycoprotein ?-dystroglycan is used as receptor by several viruses from the 
arenavirus family (Rojek & Kunz 2008). Cell culture studies of the lymphocytic 
choriomeningitis virus (LCMV) have suggested that the characteristic mannosyl 
O-glycans found on ?-dystroglycan (Moore & Hewitt 2009) are important for the viral 
infection (Imperiali et al. 2005). However, subsequent studies in knockout mice have 
indicated that the dependence of these glycans is weak in vivo (Imperiali et al. 2008). 
Glycosphingolipids 
Several studies have shown that viruses from the polyomavirus family use gangliosides as 
receptors. Using a sucrose gradient flotation assay it was demonstrated that murine 
polyoma virus specifically recognized GD1a and GT1b whereas simian virus 40 
recognized GM1a (see Fig. 10 for ganglioside structures) (Tsai et al. 2003). The study 
also showed that a C6 glioma rat cell line transfected with the GD3 synthase was poorly 
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infected by both viruses compared to non-transfected cells, where the virus establishes a 
non-productive infection. As the GD3 synthase directs ganglioside synthesis away from 
GD1a and GM1a, the resistance of the transfected cells suggests these structures to be 
required for infection with the respective virus. Furthermore, the infection could be 
restored by addition of the respective gangliosides. Similar results were achieved in 
studies with murine polyomavirus VLPs and GM95?mouse cells, lacking the 
glucosylceramidetransferase gene (Smith et al. 2003). In addition, later studies with the 
GD3 synthase transfected C6 glioma rat cell line have suggested gangliosides to be 
receptors for the bovine adeno-associated virus from the dependovirus family (Schmidt & 
Chiorini 2006).  
There is strong evidence that parvovirus B19 uses neutral GSLs as receptors. An early 
study showed that the virus agglutinated erythrocytes with the P1 and P2 but not the p 
phenotypes of blood group P (Brown et al. 1993). In contrast to the latter, the P1 and P2 
phenotypes are characterized by the expression of globotria- and globotetraosylceramide 
(Gb3, Gal?4Gal?4Glc?Cer; Gb4, GalNAc?3Gal?4Gal?4Glc?Cer). In addition, direct 
binding of virus capsids to Gb4 was demonstrated using a thin layer chromatogram 
binding assay. A subsequent publication demonstrated that, in contrast to individuals with 
the P1 or P2 phenotype, none of 11 investigated individuals with the p phenotype of blood 
group P had detectable amounts of Parvovirus B19-specific IgG antibodies (Brown et al. 
1994). These studies, together with the observation that Gb3 is only synthesized as a GSL 
(Yang et al. 1994) strongly suggest the receptor for parvovirus B19 to be a GSL. 
GSLs are also clearly involved in HIV pathogenesis even though the precise mechanism 
is not fully understood (Viard et al. 2004). Several studies have proposed 
galactosylceramide or sulfatide to function as receptors for HIV in CD4 negative cells 
such as neuroglial, colorectal epithelial and vaginal epithelial cells (Viard et al. 2004). In 
these studies, direct binding of virus to GSLs on thin layer plates and inhibition of 
infection of cells by antibodies directed against GSLs, were demonstrated. However, it is 
not clear whether these cells are infected by the virus in vivo. 
Secondly, also Gb3 and GM3 have been demonstrated to bind to HIV (Hammache et al. 
1999). In addition, these GSLs have been suggested to facilitate virus fusion (Viard et al. 
2004). However, cell culture studies with a glucosylceramide synthase inhibitor suggest 
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that the presence of Gb3 correlate inversely to susceptibility to HIV infection (Ramkumar 
et al. 2009). A protective role for Gb3 has also been suggested by studies of peripheral 
blood-derived mononuclear cells (PBMCs) from individuals with Fabry disease, who 
accumulate Gb3, (Lund et al. 2005) and from individuals with different P blood groups 
(Lund et al. 2009). The role for Gb3 in HIV pathogenesis is puzzling, as it seems to 
function as both a receptor and as a decoy receptor. A speculation about the cause of these 
contradictory results could be that Gb3 has different functions in different membrane 
domains. In that case the cells studied would differ when it comes to the distribution of 
Gb3 in the membrane. 
GSLs are also receptors for a large number of bacterial toxins (Karlsson 1995). These 
toxins typically consist of a single A subunit and five B subunits and are thus designated 
AB5 toxins. The B subunits are responsible for the attachment of the toxin. The toxic A 
subunit is subsequently delivered into the target cell. Cholera toxin is the most studied 
AB5 toxin and was demonstrated to bind to GM1 already in 1973 (Holmgren et al. 1973). 
Another AB5 toxin is the Shiga toxin which binds to Gb3 (Lindberg et al. 1987). Recently, 
a model for the mechanism by which Gb3 may function as a receptor for Shiga toxin was 
proposed (Romer et al. 2007). The toxin was demonstrated to induce invaginations in 
giant unilamellar vesicles containing phospholipids (DOPC), a fluorescent dye, 
cholesterol and Gb3. The authors proposed that the interactions between clusters of toxins 
and Gb3 induced an asymmetric stress in the membrane, which caused the invaginations. 
In analogy with this, the degree of saturation of the fatty acid of Gb3 was demonstrated to 
be crucial for the process. 
Interestingly, many of the viruses exploiting GSLs as receptors are non-enveloped. It 
could be assumed that the rigid organization of the receptor binding sites in a protein 
capsid provides better opportunities for induction of tension in the host cell plasma 
membrane, than the mobile organisation of glycan binding proteins observed in lipid 
envelopes. 
1.3.2. Receptors, species and viral tropism 
Recent RNAi screens have indicated that at least HIV, West Nile and dengue virus each 
are dependent on hundreds of host proteins for successful infection (Brass et al. 2008, 
Krishnan et al. 2008, Zhou et al. 2008). Still, the distribution of receptors is a prime 
determinant of tropism for many viruses (Arnberg 2009, Marsh & Helenius 2006, Webby 
et al. 2004). Human influenza A virus has a preference for sialic acid linked in ?2,6 
conformation to galactose whereas avian influenza A has a preference for those in a 
?2,3-linkage. To be able to infect humans efficiently, an avian influenza virus has to 
adopt to bind to ?2,6-linked sialic acid, as the target cells in the human upper respiratory 
tract express very little ?2,3-linked sialic acid (Matrosovich et al. 2004). In recent years 
about 200 humans have died from infections with avian H5N1 influenza viruses. 
Fortunately so far very limited human to human transmission of these viruses has been 
observed (Abdel-Ghafar et al. 2008). The infections seem to have been located in the 
lower respiratory tract of the infected individuals, where sialic acid in ?2,3-linkage is 
comparatively widely distributed (Shinya et al. 2006, van Riel et al. 2006). It has been 
suggested that virus from the lower airways is not as efficiently spread by sneezing and 
coughing as virus from the upper airways (Shinya et al. 2006). 
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The importance of the presence of receptors for host tropism is also illustrated by the 
successful development of a mouse model for rhinovirus infection (Bartlett et al. 2008). 
This was achieved by replacing the extracellular domain of the receptor, intracellular 
adhesion molecule 1 (ICAM-1), with the human counterpart. Another example is 
Hepatitis C virus, which has been hard to cultivate in cell culture. However, after the 
recent identification of occludin as an additional receptor for the virus, all cells 
investigated, expressing all the the four known receptors, were susceptible to infection 
with the virus (Pietschmann 2009, Ploss et al. 2009). 
1.3.3. Natural decoy receptors 
Most epithelial cells in the human body are covered by a mucus layer, acting as a physical 
barrier protecting the underlying cells from microbes, dehydration and physical as well as 
chemical injury. Major components of the mucus layer are the mucins, a family of high 
molecular weight glycoproteins (Linden et al. 2008, Thornton et al. 2008). O-glycans 
typically comprise more than 70% of the mass of mucins and are essential for the gel 
properties of the mucus layer. In addition these glycans function as decoy receptors 
trapping various microbes (Linden et al. 2008). The mucus layer is not static but moves 
and thus transports the trapped microbes away from the underlying tissue. 
1.3.4. Multivalency 
Protein-carbohydrate interactions typically show a low affinity with Kd values in the low 
mM range (Collins & Paulson 2004). However, these interactions are often strengthened 
by multivalency, which may result in an essentially irreversible binding (Mammen et al. 
1998). Many lectins are multivalent. In addition, many of the monovalent lectins are 
membrane associated and may thus be multivalently presented on the cell surface (Varki 
et al. 2008). On the glycan side of the interaction multivalency may be achieved in several 
different ways (Gabius 2008). Firstly, branching may be used to present several copies of 
an epitope on the same glycan. Secondly, one protein may present several glycans 
containing the epitope, as exemplified by mucins. Thirdly, different glycoconjugates may 
be clustered in spatial vicinity, as, for instance, GSLs in lipid rafts. The arrangement of 
multiple copies of a few capsid proteins forming a viral capsid is optimal for multivalent 
interactions. Thus, it is not surprising that most non-enveloped viruses rely on 
multivalency for cell surface attachment (Helenius 2007, Mammen et al. 1998). 
Furthermore, membrane viruses typically have multiple copies of the receptor binding 
proteins in the membrane (Helenius 2007, Mammen et al. 1998). Thus, multivalency is a 
characteristic for viral attachment, and it is not restricted to glycan binding viruses 
(Helenius 2007). 
The concept of multivalency has been extensively described (Mammen et al. 1998). 
According to the review article, the increase in avidity of a multivalent compared to a 
monovalent binding is due to a decrease in the rate of dissociation (koff), rather than an 
increase in the rate of association (kon). This can be explained by assuming that if one 
binding in a multivalent interaction is dissociated the other bonds keep the dissociated 
binding partners in close proximity, thus increasing the probability of re-binding. In 
contrast, the thermodynamic cost for the first binding in the multivalent interaction is 
approximately the same as the cost of the analogous monovalent interaction, giving the 
similar kon-values. However, the advantages of multivalency are not restricted to binding 
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strength. In the review article, a number of characteristics of multivalent interactions are 
described that are not present in monovalent interactions. The ones most applicable to 
virus carbohydrate interactions, apart from achieving very tight binding from ligands with 
low surface area, are; grading biological responses; creating new interactions by mixing, 
matching and multiplying existing ones; achieving large contacts between biological 
surfaces; inducing changes in the morphologies of large structures; inducing changes in 
the distribution of molecules in a membrane and signalling through oligomerization. 
These characteristics may be used by viruses in different steps in the entry into the host 
cell. Thus, the dependence on receptor valency for binding to one receptor, several co-
receptors or attachment factors may be used to identify and adhere to the target cell. 
Likewise, induction of changes in the morphology of the membrane or signalling 
achieved through oligomerization of receptors may be used to promote entry into the cell. 
1.3.5. Modulation of glycan presentation 
In biological systems, glycans are often used to fine tune responses (Raman et al. 2005, 
Taylor & Drickamer 2007). Glycan structures may be modulated by other mechanisms 
than multivalency. A recent study has demonstrated that the addition of the core fucose 
and the bisecting GlcNAc affects the conformation or presentation of terminal epitopes on 
N-glycans (Andre et al. 2007). In addition, these modifications were demonstrated to 
affect the glycan biorecognition, both in lectin binding studies and in studies of 
neoglycoprotein serum half time in mice. 
1.4. Host genetics and infectious diseases 
Recent advances in genomics have improved the capability to track down genes involved 
in diseases (Frazer et al. 2007). Consequently, a number of large scale genome-wide 
association studies have identified novel genes involved in complex diseases such as 
diabetes (Manolio et al. 2008). A few such large scale genome-wide association studies 
have also been conducted for infectious diseases, providing expectations for the future 
(Burgner et al. 2009, Fellay et al. 2007).  
The six strongest associations between resistance to infectious disease and common gene 
polymorphisms (minor allele frequency>0.01) identified so far are listed in Table 2 (Hill 
2006). The association between secretor status and norovirus infection is one of these 
associations. The list also includes two other associations considered to be linked to 
receptor deficiency (DARC and CCR5). Notably, both FUT2 and DARC are related to 
blood groups. 
Table 2 The strongest associations identified between resistance to infectious diseases and 
common gene polymorphisms according to Hill (2006). 
Infectious agent Gene/protein 
Plasmodium falciparum malaria Haemoglobin (sickle cell disease) 
Plasmodium vivax malaria Duffy antigen receptor for chemokines (DARC) 
Malaria Erythrocyte membrane band 3 
HIV-1 Chemokine receptor 5 (CCR5) 
Creutzfeldt-Jacob prion disease Prion protein (PRPN) 
Norovirus FUT2 
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For a number of other pathogens, weaker associations between blood groups and 
susceptibility to infection have been identified (Moulds & Moulds 2000). One example is 
the resistance of individuals with the rare p phenotype of blood group P to infection with 
parvovirus B19 (section 1.3.1). Another example is the association between blood group 
O and severe cholera infection, even though the mechanism behind this association is not 
yet understood (Glass et al. 1985, Hill 2006). 
1.4.1. Secretor status 
Secretor status has been linked to susceptibility to infection with a number of pathogens 
in addition to norovirus. Among the best characterized is the protection of secretors from 
urinary tract infections caused by E. coli (Ilver et al. 2003, Le Pendu et al. 2006). Early 
studies revealed that E. coli recognized GSLs carrying the epitope Gal?4Gal, 
characteristic for the globoseries (Bock et al. 1985). Later, two extended globoseries 
GSLs (Neu5Ac?3Gal?3GalNAc?3Gal?4Gal?4Glc?Cer and 
Neu5Ac?3Gal?3(Neu5Ac?6)GalNAc?3Gal?4Gal?4Glc?Cer), were shown to be 
especially good binders (Stapleton et al. 1998). The basis for the association between 
susceptibility to urinary tract infection and secretor status seems to be that these two 
glycolipids are specific for non-secretors. In secretors, the biosynthesis is instead directed 
towards Globo H (H type 4) (Fuc?2Gal?3GalNAc?3Gal?4Gal?4Glc?Cer), which is a 
weaker binder (Ilver et al. 2003). Non-secretors have also been suggested to be 
predisposed to infections with Haemophilus influenzae, Neisseria meningitidis and 
Streptococcus pneumoniae, even though the basis for these associations has not been 
resolved (Le Pendu et al. 2006). A recent study has suggested that children with the Lea+b- 
phenotype have increased susceptibility to diarrhea caused by enterotoxigenic E. coli 
expressing colonization factor I group fimbriae (Ahmed et al. 2009).  
In contrast to the mentioned bacterial infections, non-secretors are underrepresented 
among patients suffering from infections with influenza viruses A and B, rhinoviruses, 
respiratory syncytial virus and echoviruses (Raza et al. 1991). In addition, two studies 
have suggested a lower risk for non-secretors of getting infected with HIV-1 (Ali et al. 
2000, Blackwell et al. 1991). In contrast, one study has reported the opposite association, 
or more precisely a lower Lea-b+ phenotype frequency among HIV infected patients 
compared to healthy blood donors (Puissant et al. 2005). Furthermore, a recent study has 
identified an association between FUT2 genotype and HIV-1 progression, with non-
secretors being overrepresented among long-term non-progressors compared to 
progressors (Kindberg et al. 2006).  
Many studies have investigated associations between H. pylori infection and secretor 
status, as the BabA adhesin recognizes secretor gene dependent glycans (Boren et al. 
1993, Ilver et al. 1998). However, the association does not seem to be as strong as 
expected (Azevedo et al. 2008), probably because of the many other binding specificities 
identified for the bacterium (Angstrom et al. 1998, Gold et al. 1993, Kamisago et al. 
1996, Mahdavi et al. 2002, Miller-Podraza et al. 2009, Teneberg et al. 2002). The 
possibilities for an association between secretor status and predisposition to infection and 
lung disease in cystic fibrosis patients have also been discussed. However in a recent 
study including 808 patients homozygous for the ?F508 mutation in the cystic fibrosis 
gene, no polymorphisms in the ABO, FUT2 or FUT3 genes were found to correlate with 
severity of disease or P. aeruginosa infection (Taylor-Cousar et al. 2009). 
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Secretor status has also been associated with non infectious diseases. In a recent genome-
wide study to identify loci that influence plasma vitamin B12 levels, a strong association 
to FUT2 was identified. Non-secretors showed higher B12 levels than secretors  (Hazra et 
al. 2008). 
1.5. Norovirus-glycan interactions 
Clinical studies during the late 1970s and early 80s were confusing concerning the linkage 
between antibodies against the Norwalk virus and susceptibility to illness (Baron et al. 
1984, Dolin et al. 1972, Parrino et al. 1977). Especially puzzling was that some 
individuals who didn’t have antibodies against norovirus were constantly resistant to 
challenge (Johnson et al. 1990). In addition, a study published in 1982 indicated a familial 
clustering of resistance to norovirus, suggesting a genetic factor to be involved (Koopman 
et al. 1982). 
The successful production of norovirus VLPs facilitated binding studies to search for 
potential receptors (Jiang et al. 1992). A breakthrough came in 2000 when RHDV was 
demonstrated to bind to the histo-blood group antigens H type 2 and A type 2 (Ruvoen-
Clouet et al. 2000). 
1.5.1. Norwalk virus challenge studies and VLP binding studies 
Two years after the demonstration that RHDV recognized ?1,2-fucosylated glycans 
(Ruvoen-Clouet et al. 2000) researchers from the same group showed that the Norwalk 
virus VLP also recognized the H antigen (Marionneau et al. 2002). In contrast to RHDV, 
the Norwalk virus primarily recognized H antigens based on the type 1 and type 3 chains. 
This study also showed that Norwalk VLPs recognized epithelial cells of the 
gastroduodenal junction from secretor-positive, but not from secretor-negative 
individuals. A challenge study demonstrating the resistance of non-secretors to infection 
with the Norwalk virus was published in 2003 (Lindesmith et al. 2003). A few years later 
the authors of an earlier challenge study were able to include secretor status in their 
analysis, by genotyping for secretor status using the serum samples available (Hutson et 
al. 2005). Together these two challenge studies included 97 secretors and 30 non-
secretors. Seventy-six of the secretors, but none of the non-secretors, showed symptoms 
of infection, excreted detectable amounts of viral RNA in feces or showed an increase in 
anti-Norwalk virus antibody titers. Furthermore, even though not statistically significant, 
secretor-positive blood group B individuals were underrepresented among the infected in 
both studies. In addition, in vitro studies showed weaker binding for Norwalk virus VLPs 
to saliva from secretor-positive B than from A and O individuals (Harrington et al. 2002a, 
Lindesmith et al. 2003, Marionneau et al. 2005). Similarly, another study showed that 
Norwalk VLPs hemagglutinated blood group O, A an AB erythrocytes, but only few 
blood group B erythrocyte samples (Hutson et al. 2003). 
1.5.2. Binding studies of other norovirus VLPs 
The glycan repertoire of the mucins in saliva resembles the one on the epithelial cells in 
the gastrointestinal tract (Ravn & Dabelsteen 2000). A number of studies have used 
ELISAs with immobilized saliva samples to study norovirus binding (Marionneau et al. 
2002, Tan & Jiang 2005a). VLPs from a large number of norovirus strains have been 
assayed against saliva samples from individuals of different ABO(H) and Lewis histo-
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blood groups (Table 3). Binding information for specific glycans have been achieved in a 
similar assay with immobilized neoglycoproteins or polyacrylamide (PAA) 
glycoconjugates.  
By combining the saliva ELISA and the neoglycoprotein/PAA ELISA, different binding 
patterns have been identified for different strains of noroviruses (Harrington et al. 2002a, 
Huang et al. 2003, Huang et al. 2005, Shirato et al. 2008). A general conclusion from 
these studies is that most strains from the clinically common genoclusters only bind to 
saliva samples from secretor-positive and not from secretor-negative individuals. One 
group consisting of the VA387 and Grimsby VLPs, both from the dominating GII.4 
genocluster, showed binding to secretor-positive individuals of all ABO groups whereas 
another group did not recognize saliva from blood group O individuals (Table 3). In the 
latter group the Paris Island (GII.3) and MOH (GII.5) VLPs were localized since they 
only recognized saliva from secretor-positive blood group A and B individuals. The 
Mexico (GII.3) strain recognized saliva from secretor-positive blood group A individuals 
only, but was included in this group as it recognized BSA conjugated with the B 
trisaccharide. Interestingly, some strains showed a secretor gene independent binding 
pattern. Of these, one group (best exemplified with the VA207 strain (GII.9)) seems to 
recognize ?1,4-linked fucoses and consequently binds to saliva from all Lewis positive 
Table 3 The saliva binding pattern of a number of VLPs, as determined by ELISA with saliva 
samples from non-secretors and secretors of blood group O, A and B. The binding strength 
have been scored as no binding (-), intermediate binding (+) and strong binding (++). The data 
is adapted from Harrington et al. (2002a), Huang et al. (2005), Lindesmith et al. (2008) and 
Marrioneau et al. (2005). 
Secretor Strain Genocluster Non-
secretor O A B 
VA387 GII.4 - + ++ ++ 
Grimsby GII.4 - + ++ ++ 
1987 GII.4 - ++ ++ ++ 
1997 GII.4 - ++ ++ ++ 
2002 GII.4 - ++ ++ ++ 
NV GI.1 - ++ ++ + 
MOH GII.5 - - ++ + 
Paris island GII.3 - - + + 
Mexico GII.3 - - ++ - 
C59 GI.2 - - + - 
BUDS GII.2 - - ++ - 
SMV GII.2 - - - + 
VA207 GII.9 + + + - 
OIF GII.13* ++ + - - 
2002a GII.4 + ++ ++ ++ 
DSV GI.3 - - - - 
VA115 GI.3 - - - - 
Hawaii GII.1 - - - - 
2004 GII.4 - - - - 
2005 GII.4 - - - - 
* 81 % amino acid identity to Fayetteville, GII.13 
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individuals. In addition, some strains (e.g. DSV (Desert shield virus, GI.3) and Hawaii 
(GII.1)) did not recognize any saliva samples or neoglycoconjugates assayed. When 
comparing the amino acid sequence of the major capsid protein, strains with a similar 
binding pattern tended to cluster in the phylogenetic tree (Huang et al. 2005). However, 
no clear correlation could be established suggesting that a small number of amino acid 
mutations may alter the binding pattern. In support of this, a recent study has suggested 
that VLPs from different epidemic groups of GII.4 strains show differences in binding 
pattern (Table 3) (Lindesmith et al. 2008). Notably, one VLP constructed from a strain 
isolated in 2002 (2002a), bound to saliva from both secretors and non-secretors. However, 
these different GII.4 binding patterns have been questioned in a study from another 
research group (Tan et al. 2008c). 
The results from the saliva and neoglycoconjugates ELISAs have been validated by 
experiments showing that the VLP-binding may be blocked by anti-blood group specific 
antibodies or glycosidases (Huang et al. 2003, Huang et al. 2005). In addition, the 
interaction between norovirus VLPs and glycans has been studied in a few other assays. A 
reversed ELISA, where VLPs were immobilized and interacting biotinylated 
polyacrylamide conjugates assayed for binding, was reported (Harrington et al. 2002a). In 
recent studies surface plasmon resonance has been used for label-free detection of VLPs 
binding to immobilized monovalent glycans (Shirato et al. 2008) and multivalent 
glycoconjugates (Choi et al. 2008). 
In addition to VLP binding studies, RT-PCR has been used to detect norovirus captured 
from clinical stool specimens using magnetic beads conjugated with glycans (Harrington 
et al. 2004). Native viruses have also been assayed in the traditional saliva-ELISA 
(Thorven et al. 2005). Even though no systematic comparison has been performed 
between the binding characteristics of VLPs and native viruses, the studied native viruses 
showed similar binding patterns compared to the related VLPs. The relevance of the use 
of VLPs is furthermore strengthened by the match between VLP binding and infectivity 
of the Norwalk virus (Harrington et al. 2002a, Hutson et al. 2005, Lindesmith et al. 2003, 
Marionneau et al. 2005). As described in the next section GI.3 viruses show similar 
patterns in infectivity and saliva binding (Nordgren 2009, Shirato et al. 2008). 
A limitation to most of the neoglycoconjugates used in the described binding studies is 
that the glycans are short, composed merely of the minimal antigen epitopes. Thus, the 
impact of different core structures and modifications closer to the reducing end has been 
poorly addressed. 
In addition to the binding to ABO(H) and Lewis histo-blood group structures a specific 
binding of norovirus VLPs have been identified to heparan sulfate (Tamura et al. 2004). 
In this study three GII VLPs were shown to bind to a number of cell types in a heparan 
sulfate dependent manner, whereas two GI VLPs bound only weakly via heparan sulfate. 
Cell culture binding of the GII VLPs could be blocked by preincubating the VLPs with 
the glycosaminoglycans heparan sulfate, chondroitin sulfate and dermatan sulfate, but not 
with hyaluronic acid which lacks sulfate groups. Heparan sulfate was suggested to be the 
cell surface molecule responsible for the binding since pre-treatment of the cells with 
heparinase, but not with chondrotinase, reduced the binding. 
The principal novel finding that GII VLPs also recognize SLex and structural analogues, 
as described in Paper II, will be discussed in section 4.2. 
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1.5.3. Outbreak studies 
The influence of the secretor status on susceptibility to norovirus infection in authentic 
norovirus outbreaks was investigated firstly in Sweden (Thorven et al. 2005). In the 
study, 38 symptomatic individuals from three outbreaks caused by GII.4 strains at a 
hospital were genotyped for secretor status. The same analysis was performed on 15 
symptomatic individuals from three community outbreaks caused by GI.6 and GII.6 
strains. Thus, in total, 53 symptomatic and 62 asymptomatic individuals were genotyped 
for polymorphisms of FUT2 at nt 385, 428 and 571. As expected, mutations were 
identified only at nt 428. Strikingly, no non-secretors were identified among the 
symptomatic individuals. Fischer’s exact test was used to show that the distribution of 
secretor status was significantly different between the symptomatic and asymptomatic 
individuals (p<0.00001) as well as between the symptomatic individuals and 104 Swedish 
blood donors (p<0.0002). As the secretor status was determined by genotyping, the 
influence of homozygosity and heterozygosity could be determined. No difference was 
identified between heterozygous and homozygous secretors. Subsequently, the resistance 
of non-secretors to GII.4 strains in authentic outbreaks has been confirmed by a similar 
study in Denmark (p<0.003, symptomatic vs asymptomatic) (Kindberg et al. 2007). 
Similar results were also obtained in a study of a GII.4 outbreak in China (p<0.003, 
symptomatic vs asymptomatic), where secretor status was determined by phenotyping of 
saliva samples in an ELISA with monoclonal antibodies. (Tan et al. 2008b). In the latter 
study, the weak-secretors were grouped with the secretors. In addition, a number of 
studies of noroviruses from other genogroups have reported that only secretors were 
identified among the symptomatically infected patients, even though the materials were 
not large enough to prove any statistical correlation (Bucardo et al. 2009, Tan et al. 
2008b).  
Reports of symptomatic infections in non-secretors do exist. In one study, 4 out of 24 
symptomatically infected individuals were found to be non-secretors (Rockx et al. 
2005b). The GI.3 virus, causing the outbreak investigated, could be detected in stool 
samples from all four of the infected non-secretors. The secretor status was determined by 
measuring the inhibition potential of saliva samples in a microtiterplate hemagglutination 
assay with blood group O erythrocytes and an anti-H lectin. Similar results were achieved 
in a recent study of a GI.3 outbreak in Sweden. Using both pheno- and genotyping, 7 out 
of the 33 symptomatic individuals in the outbreak were shown to be non-secretors 
(Nordgren 2009). In addition, even though not statistically significant an unexpectedly 
low proportion of the symptomatic individuals in these studies were blood group B 
secretors, indicating a similar protection of these individuals as observed for the Norwalk 
virus. Interestingly, the disease profile identified for these GI.3 strains agrees with the 
saliva and neoglycoconjugate binding pattern of a GI.3 VLP (Shirato et al. 2008). In 
addition, infection of one non-secretor (geno- and phenotyped), has been demonstrated in 
a challenge study with the Snow Mountain virus (GII.2) (Lindesmith et al. 2005).  
A few additional outbreak studies have addressed the impact of ABO-blood group and 
Lewis status as well as secretor status on susceptibility to norovirus infection (Bucardo et 
al. 2009, Tan et al. 2008b). The already described Chinese outbreak study demonstrated 
that blood group A individuals were overrepresented among the infected individuals 
compared to the asymptomatic individuals (p<0.02) (Tan et al. 2008b). Blood group O 
individuals, in contrast, showed the opposite distribution (p<0.03). No binding studies 
 29 
were performed with VLPs representing this outbreak virus or the outbreak virus itself. 
However, it is interesting to note that many GII.4 VLPs recognize saliva samples from 
blood group O individuals less well than those from blood group A, B and AB individuals 
(Table 3). 
1.5.4. Protective effects of human milk 
Human milk is known to contain histo-blood group antigens in the form of free glycans, 
GSLs and glycoproteins (Le Pendu 2004). In vitro studies have demonstrated that milk 
from secretor mothers, in contrast to non-secretor mothers, inhibits binding of norovirus 
VLPs to ?1,2-fucosylated glycans (Jiang et al. 2004, Le Pendu 2004). Phenotyping of 
milk samples have suggested that the blood group A and B antigens are not expressed in 
milk (Jiang et al. 2004). In analogy with this, no blocking activities were observed for the 
MOH (GII.5) VLP recognizing only blood group A and B antigens (Jiang et al. 2004). 
Clinical evidence of breast-feeding protection of infants has been obtained in an infant-
mother cohort in Mexico (Morrow et al. 2004). Calicivirus infections occurred less often 
in infants fed with milk containing higher levels of ?1,2-linked fucoses. 
1.5.5. The viral carbohydrate binding sites 
One study of Norwalk virus VLP binding to CaCo-2 cells described a monoclonal 
antibody that could inhibit the virus from binding to the cells (White et al. 1996). The 
antibody binding epitope was mapped to the P2 domain of the capsid protein, suggesting 
this domain to be responsible for the cell binding. In addition, the demonstration that P 
particles and P dimers, but not S particles, maintained the binding specificities of the 
corresponding VLPs strongly suggested the binding site to be located in the P domain 
(Tan et al. 2004a, Tan & Jiang 2005b). A conserved RGD motif, surrounded by strain 
specific amino acids, was identified in the P2 domain by multiple sequence alignment 
analysis (Tan et al. 2003). Site-directed mutagenesis suggested the identified motif to be 
involved in the binding pocket. In another study, evolutionary trace was used to locate the 
binding pocket to another position (Chakravarty et al. 2005). Alignment analysis followed 
by a superimposition on the Norwalk virus capsid protein structure suggested the two sites 
to be distinct, but located close to each other (Chakravarty et al. 2005).  
The location of the actual binding pocket was eventually revealed when the X-ray crystal 
structure of the P dimer of the GII.4 strain VA387 in complex with the blood group B 
trisaccharide was solved (Fig. 11) (Cao et al. 2007). In fact, the amino acids proposed by 
the evolutionary trace studies (Chakravarty et al. 2005) were surrounding the binding 
pocket. The crystal structure showed that the ?1,2-linked fucose was tightly bound by 
interactions with 7 amino acids, all highly conserved in GII strains. The terminal ?Gal 
residue was also bound whereas the ?Gal residue seemed to act more like a scaffold. 
Subsequently, the amino acids involved in the recognition of the glycans have been 
confirmed by site-directed mutagenesis (Tan et al. 2008c). The structure of co-crystals, 
identifying the binding site of the Norwalk virus has also been solved (Bu et al. 2008, 
Choi et al. 2008). Interestingly, this site has a location distinct from the binding site in the 
VA387 structure. One of the Norwalk structures revealed the basis for the binding to 
blood group A- and H-, but not B-terminated glycans (Choi et al. 2008). The structure 
showed that the ?Fuc residue of the H type 1 structure and the ?GalNAc residue of the A 
structure were engaged in similar hydrophobic interactions with a tryptophan (Trp-375). 
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This interaction may not take place for the ?Gal residue of blood group B structures, as 
this has a hydroxyl group instead of an N-acetamido group. Thus, the H type 1 
pentasaccharide and the A trisaccharide were bound in the same binding site, but in 
different modes. Furthermore, the ?Fuc seemed to be minimally involved in the binding 
of the blood group A trisaccharide. 
1.6. Antiviral therapy 
1.6.1. Attachment inhibitors 
Viruses constitute a diverse group of infectious agents and so far no common Achilles’ 
heel has been identified to exploit for therapy against viruses. Thus, no drugs comparable 
to the bacterial broad spectrum antibiotics have been developed for viruses (Coen & 
Richman 2007).  
Inhibition of viral attachment is an appealing antiviral strategy as it prevents all 
subsequent steps in the infection process and keeps the virus accessible for the immune 
system. Furthermore, the possibility for pathogens to develop resistance to a drug 
targeting the receptor binding site is expected to be low. This is because most amino acids 
interacting with the receptor must be conserved to keep the interaction (Coen & Richman 
2007).  
Anti-adhesion drugs mimicking glycans are not only of relevance for virus therapy, but 
also against glycan binding bacteria and bacterial toxins (Bovin et al. 2004, Collins & 
Paulson 2004, Imberty et al. 2008, Mammen et al. 1998). Furthermore, much effort has 
been invested in the development of selectin antagonists based on SLex-analogues, with 
applications for inflammatory diseases and cancer metastasis (Magnani 2004). Promising 
in vivo results for glycan based anti-adhesins have been obtained with dendrimers 
containing the globo trisaccharide (Gal?4Gal?4Glc) in studies of mice challenged with 
Shiga toxin or enterohemorrhagic E. coli (Mulvey et al. 2003, Nishikawa et al. 2002). 
Other promising examples are the various sulfated polysaccharides that are in clinical 
trials as therapy against herpes simplex virus and as anti HIV-1 drugs (Ghosh et al. 2009). 
 
Figure 11 
The blood group B trisaccharide in the 
binding pocket of the VA387 (GII.4) strain. 
The coordinates were obtained from PDB 
id 2obt Cao et al. (2007) and the image 
was generated using Sybyl (Tripos Inc., St 
Louis). The surface of the protein is color 
coded according to the distance between 
the glycan and the surface residues with a 
cut-off of 3Å. By courtesy of C. Koppisetty, 
Biognos AB. 
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Most attachment inhibitors are multivalent. The multivalency does not only enhance the 
binding strength, i.e. the competitive inhibition, but also provides the ability to block 
interactions through steric hindrance (Mammen et al. 1998). An additional mechanism for 
inhibition may be agglutination of the pathogens. Design of effective multivalent 
attachment inhibitors requires consideration of both enthalpy and entropy (Mammen et al. 
1998). To make it simple: a flexible scaffold molecule has a large entropic cost upon 
binding whereas a rigid molecule has a large enthalpic cost, unless the geometric fit is 
perfect. In this aspect, bacteria and enveloped viruses, with mobile lectins may require 
different approaches than bacterial toxins and non-enveloped viruses with more rigid 
structures. The increasing structural information on carbohydrate-protein interactions 
provides opportunities for a structural design of inhibitors (Imberty & Varrot 2008, von 
Itzstein 2008). An alternative approach to synthetic constructs, is to genetically engineer 
probiotic bacteria to express receptor glycans for pathogens on their surface (Paton et al. 
2006). 
An example of a monovalent attachment inhibitor is Pleconaril (De Palma et al. 2008). 
This drug is in clinical trials for treatment of the common cold, caused by rhinovirus 
infection. The receptor (ICAM-1) binding site is located in a deep surface repression on 
the viral capsid and was early hypothesized to be inaccessible for antibodies (Rossmann 
1989). Pleconaril binds into a hydrophobic pocket located underneath the floor of the 
receptor binding site. In the absence of the drug, this pocket is occupied by a lipid, 
suggested to be sphingosine (Ding et al. 2002). The binding of Pleconaril alters the 
conformation of the receptor binding site and hampers the binding to the receptor. As a 
second mechanism, the drug increases the rigidity of the virion, which prevents the 
uncoating process. 
An alternative to blocking the receptor binding pocket on the pathogen is to target the 
receptor on the host cell. This has been a fruitful approach for HIV. One drug directed 
against the HIV co-receptor CCR5 has been approved and others are in clinical trials (Fox 
2007). In analogy with the effect of these drugs, individuals who are homozygous for the 
?32 deletion in CCR5 are protected from HIV-1 infection (Dean et al. 1996). However, 
these individuals seem to have an increased susceptibility for infection with West Nile 
virus (Lim et al. 2006) and tick-borne encephalitis (Kindberg et al. 2008), which may 
have implications for usage of these drugs. Based on the successful treatment of patients 
with GSL storage diseases using glycosylation inhibitors, the use of these substances as a 
therapy against infections caused by GSL binding pathogens has been proposed 
(Svensson et al. 2006).  
1.6.2. Other antiviral drugs 
Among the most successful antiviral drugs are the protease and reverse transcriptase 
inhibitors directed against HIV, the interferon therapy for hepatitis B and C, Amantadine 
against influenza virus A and the neuraminidase inhibitors against influenza virus (Levine 
& Enquist 2007, von Itzstein 2007). The majority of the more than forty antiviral drugs 
approved are directed against viral enzymes (Coen & Richman 2007). 
1.6.3. Vaccines 
Vaccination is an efficient method to prevent viral infections. The complete elimination of 
natural smallpox by vaccination is among the most remarkable medical achievements of 
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the last century (Levine & Enquist 2007). The present Swedish national vaccination 
program includes vaccination against polio, measles, mumps and rubella virus. In total, 
vaccines have been developed for about 15 viral pathogens infecting humans (Graham & 
Crowe Jr 2007). Most vaccines generate long time immunity, whereas for the influenza 
virus new vaccine has to be developed for every season, because of the extensive 
antigenic drift. To be effective, a vaccine must generate neutralizing antibodies towards 
the virus. Since most such antibodies are directed against the receptor binding site on the 
virus, knowledge about the virus-receptor interaction is of relevance for vaccine 
development. 
1.6.4. Anti-norovirus therapy 
Only very few and recent studies have presented attachment inhibitors for norovirus. One 
study presented inhibitors based on ?1.2-fucosylated glycans conjugated to hydrogels 
(Zhang et al. 2006). Another study identified 14 molecules showing 50% inhibition at 
<15?M in a VLP-saliva ELISA through a screening of a library of 5000 drug-like small 
molecules? (Feng & Jiang 2007). 
For several reasons we consider norovirus a promising target for anti-adhesion therapy. 
Firstly, the potential of abolishing the interaction between norovirus and ?1,2-fucosylated 
glycans has been demonstrated in challenge and outbreak studies of different norovirus 
strains. In addition, the protection from gastroenteritis of breast-fed infants with secretor 
mothers is a direct indication of the potential of inhibiting the virus-glycan interaction 
(Morrow et al. 2004). Secondly, vaccine development for norovirus is challenging 
because of the complex immunity and the large antigenic diversity between different 
strains (Estes et al. 2000, LoBue et al. 2009, Tanaka et al. 2006). The recent 
demonstration of epochal evolution of norovirus GII.4 strains suggest that new vaccines 
have to be developed as new epidemic variants emerge similarly to the influenza vaccine 
(Allen et al. 2008, Lindesmith et al. 2008, Siebenga et al. 2007). Thirdly, norovirus 
infection is well suited for prophylactic therapy, given the large outbreaks caused in 
closed settings such as hospitals and cruise ships. This is of importance as the largest 
effect of anti-adhesion therapy is expected to appear when administered prior to 
exposition to the pathogen, in analogy with the neuraminidase inhibitors for influenza 
virus (Moscona 2005). Finally, the administration of a norovirus inhibitor may be simple, 
as it is to function in the gastrointestinal tract as a decoy mechanism. Thus, the drug does 
not have to be optimized for uptake or distribution, which lowers the risk for side effects 
in the rest of the body.  
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2. Aim 
The aim of this thesis is to characterize the interactions between human noroviruses and 
host cell surface glycans. Knowledge about the carbohydrate binding specificities and the 
kinetics of different strains of norovirus may be used not only to predict susceptibility to 
infection, but also for development of anti-adhesion therapy. The long term goal of this 
study is to design a drug inhibiting the attachment of norovirus to host cell glycans. 
The specific aims are: 
? To investigate whether norovirus specific IgG antibody prevalence and titer 
correlate with secretor, Lewis or ABO histo-blood group status in Swedish blood 
donors. 
? To characterize the glycan binding characteristics of human norovirus VLPs using a 
wide array of structurally and antigenically well defined glycoconjugates: 
o Saliva samples from Swedish blood donors, well characterized according to 
secretor, Lewis and ABO histo-blood group status 
o Neoglycoconjugates, with oligosaccharides synthetically linked to albumin or 
polyacrylamide 
o Glycosphingolipids, as naturally occurring membrane bound glycoconjugates 
? Chromatographed on thin layer-plates 
? Incorporated in laterally fluid supported lipid bilayers 
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3. Methodological considerations 
3.1. Virus-like particles as a model for norovirus 
One of the major obstacles in research on norovirus has been, and still is, the lack of cell 
culture methods for propagation of the virus. Consequently, most of the knowledge about 
the virus stem from epidemiological studies, challenge studies and studies using VLPs. 
When this thesis project started the murine norovirus had just been discovered (Karst et 
al. 2003) even though the propagation of the virus in mouse dendritic cells and 
macrophages was still to be revealed (Wobus et al. 2004). However, the symptoms of the 
norovirus infection in mice differ from the human norovirus infection (section 1.1.9). In 
addition, the glycome of the small intestine differs between mice and humans, as GSLs of 
the ganglioseries (and not of the lactoseries) are the most prominent in epithelial cells of 
mouse small intestine (Hansson et al. 1982, Iwamori & Domino 2004). When taking these 
aspects together, we considered VLPs to be the most favourable model to study human 
norovirus-host glycan interactions. The VLPs used are described in Table 4 and were 
produced in insect Sf9 cells using the baculovirus system (Jiang et al. 1992). VLPs may 
also be produced in mammalian cells using the venezuelan equine encephalitis virus 
system (Baric et al. 2002). This system, however, requires a high level of safety measures 
during laboratory work. Since the VLPs used in this thesis have been produced in 
different labs, some minor differences between the production protocols exist. Notably, 
the Houston VLP was produced using a recombinant baculovirus which contained the 
open reading frames coding for both the major and minor capsid proteins. In contrast, the 
baculoviruses used for the production of the other VLPs contained the open reading frame 
coding for the major capsid protein only. The Norwalk virus is the prototype norovirus 
strain and belongs to GI.1. The Chron1 strain belongs to GII.3 and was isolated from the 
first viral isolate from the chronically infected patient described in section 1.1.2 and 
1.1.10. The Dijon and Houston strains both belong to GII.4, the genocluster responsible 
for more than half of all outbreaks of norovirus (section 1.1.5). The Dijon strain was 
isolated from an outbreak in France during the winter 1995-1996 (Nicollier-Jamot et al. 
2003). The Houston strain was isolated from a stool sample from a 2-month old boy with 
gastroenteritis who was seen at the Texas Children’s hospital in Houston in 2002 (Paper 
I). 
3.2. Typing for ABO(H) and Lewis blood group status  
The ABO(H) and Lewis blood group status of an individual may be determined either by 
pheno- or genotyping. In phenotyping, antibodies or lectins are used to detect the presence 
of the specific antigens, characterizing the various blood groups. In genotyping various 
Table 4 The VLPs studied in this thesis. 
Name cluster Genbank no Used in Original reference 
Norwalk (NV) GI.1  AAB50466 Paper II, III & IV Jiang et al. 1992 
Chron1  GII.3 AAP03029  Paper II Paper II 
Dijon GII.4 AAL79839 Paper II, IV Nicollier-Jamot et al. 2003
Houston (HOV) GII.4 ABY27560 Paper I Paper I 
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SNPs, known to characterize the activities of the enzymes synthesizing the antigens, are 
analyzed. 
The main problem with phenotyping is the cross-reactivity of the antibodies (Manimala et 
al. 2007). Accurate phenotyping thus often requires the use of several different 
monoclonal antibodies. Clinically, phenotyping for the ABO(H) Lewis blood group 
antigens is mainly performed on erythrocytes (section 1.2.3). In the norovirus field, 
phenotyping has commonly been performed on saliva samples, which are used also for 
VLP-binding studies.  
The major disadvantage with genotyping is that usually only the known SNPs are 
characterized. Uncommon inactivating mutations may thus be missed, leading to false 
positive results. FUT2 genotyping in the Caucasian population is straight forward, since 
the G428A mutation is so dominating. In our lab about 300 Caucasians have been 
genotyped without ever finding the A385T or C571T mutations. 
3.2.1. Saliva and plasma samples 
The plasma and saliva samples used in Paper I and II are uniquely well characterized 
according to the secretor, Lewis and ABO blood group status of the donors. The material 
was collected from healthy donors arriving at the Sahlgrenska University hospital for 
plasmapheresis. From 105 individuals, EDTA-anticoagulated plasma was obtained and 
separated into plasma, buffy coat and erythrocytes. All of the 105 donors were 
phenotyped for ABO blood groups by hemagglutination and genotyped for inactivating 
FUT2 G428A and FUT3 T59G, T202C, C314T, G508A, T1067A point mutations. Fixed 
erythrocytes from 93 of the donors were in addition analyzed for Lewis blood groups by 
fluorescence activated flow cytometry (FACS) and the results were compared to the 
hemagglutination scores (Larson et al. 1999). Saliva samples were obtained from 81 of 
the 105 donors. These samples were collected as mixtures of parotid, sublingual, and 
submandibular secretions and stored at -20 ?C. In Paper II, the material was further 
characterized by phenotyping the saliva samples for Lea, Leb, A, B and SLex antigens 
using ELISA. 
The ABO(H) Lewis histo-blood group distribution of the material is presented in Table 1 
in Paper I. The histo-blood group distribution of the individuals donating saliva samples is 
presented in Figure 2 in Paper II. 
3.3. Glycosphingolipids 
The GSLs used are listed in Paper III and were purified essentially as described (Karlsson 
1987). The type 1 series GSLs originate from human meconium samples from single 
individuals or from meconium samples pooled according to ABO blood groups. The other 
reference GSLs used in this thesis originate from human erythrocytes pooled according to 
ABO blood groups or from the small intestines of dogs. The identity and purity of the 
reference GSLs were analyzed by 1H-NMR spectroscopy (Paper III). Chemical shifts and 
coupling constants for the H1 anomeric protons and fucose H-5 and H-6 protons were 
compared to published values (Angstrom et al. 2004, Clausen et al. 1986, Clausen et al. 
1985a). This analysis complemented previous characterizations by 1H-NMR and mass 
spectrometry (Angstrom et al. 1982, McKibbin et al. 1982). Figure 12 shows the 
anomeric region of the 1H-NMR spectra of the H type 1 and Lea GSLs, used in Paper III 
and IV. 
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3.4. Antibody titers 
An ELISA with immobilized VLPs was established to determine titers of norovirus 
specific IgG antibodies. The assay was used together with human serum samples in Paper 
I and is described there.  
3.5. VLP binding studies 
An ELISA was used to study VLP binding to saliva samples, serum albumin 
neoglycoconjugates and PAA neoglycoconjugates, whereas CBA and Quartz crystal 
microbalance with dissipation (QCM-D) monitoring was used to study VLP binding to 
GSLs. Antibodies were used for VLP detection in the ELISA. The CBA was established 
using radiolabeled VLPs, but was also used together with antibody detection. QCM-D is a 
label-free method not requiring use of antibodies.  
3.5.1. ELISA 
The most commonly used assay for characterization of norovirus VLP interactions with 
glycans is an ELISA with immobilized glycoconjugates (section 1.5.2). We used such an 
assay to study VLP binding to saliva samples and serum albumin conjugates. For the 
saliva samples we chose to coat saliva according to protein concentration, even though in 
most other studies coating has been according to certain dilutions. The reason for coating 
according to protein concentration was mainly to correct for differences in water content 
between the saliva samples. For detection of bound VLPs antisera obtained by 
immunizing rabbits or mice with purified VLPs were used. In addition also a human 
antiserum, of a blood group ABLeSe individual with a high titer of anti norovirus 
antibodies was used. An inhibition-ELISA was also established, where the VLPs were 
preincubated with inhibitors, before being added to wells coated with either saliva or 
neoglycoproteins. 
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Figure 12 
The anomeric region of the 1H-NMR spectrum of the H type 1 and Lewis a GSLs in 
DMSO:D2O (98:2) at 303 K with corresponding shifts for each monosaccharide indicated. 
Both GSLs were judged to be more than 98% pure. 
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An inverted ELISA was established for the PAA conjugates. Thus, VLPs were coated and 
interacting biotinylated PAA conjugates detected using peroxidase conjugated 
streptavidin. Because Norwalk VLPs have been reported to dissociate at pH above 8 
(Ausar et al. 2006) the coating buffer for this assay was changed from carbonate buffer 
(pH 9.6) to PBS (pH 7.2). Notably, no antibodies were used in this assay. However, these 
experiments complemented results obtained with the standard ELISA.  
The glycoconjugate ELISAs were mainly used in Paper II and are thoroughly described 
there. The neoglycoproteins and PAA conjugates used are listed with complete structures 
in Table I in the same paper. 
3.5.2. Chromatogram binding assay 
The chromatogram binding assay (CBA) is a classical method for studies of protein-GSL 
interactions. In this method GSLs are chromatographed on thin layer plates. Thereafter 
the plates are coated with plastic and overlayed with the glycan binding protein studied. 
The method was originally established for studies of interactions between cholera toxin 
and gangliosides (Magnani et al. 1980) and later for studies of other glycan binding 
proteins including viruses (Hansson et al. 1984). A CBA enables screening for binding 
structures in complex mixtures of GSLs. However, use of pure substances is preferred to 
accurately demonstrate binding activity for specific GSLs. The methodology has been 
extensively described (Karlsson & Stromberg 1987).  
In Paper III a CBA was used together with 125I-labeled Norwalk VLPs. The results were 
confirmed in Paper IV using antibody detection of non-labeled VLPs. The antibody 
detection was less sensitive than the radiography detection of 125I-labeled VLPs and thus 
required higher concentrations of VLPs to be used. The CBA is described in detail in 
Paper III. 
Radiolabeling of VLPs using ATE 
In Paper III a method for radiolabeling of VLPs via an activated tin-containing ester 
(ATE, N-succinimidyl-3-tributylstannyl benzoate) was established (Fig. 13) (Garg et al. 
1993). The alkylstannyl group of this compound is a good leaving group in the 
electrophilic substitution reaction with iodine resulting in the formation of a 
125I-containing succinimidyl ester. In the second step, this ester is conjugated to accessible 
lysine residues on the VLP. This two-step procedure admits quenching of the oxidizing 
agent before the addition of the protein, which eliminates the risk of oxidative damage to 
the protein. The ATE method thus provides a milder treatment of the VLPs than the 
commonly used Iodo-Gen method (Fraker & Speck 1978). The major advantages with the 
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Figure 13 
The chemical principles for iodination of VLPs using N-succinimidyl-3-tributylstannyl benzoate (ATE). 
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ATE method compared to the similar Bolton-Hunter method (Bolton & Hunter 1973) are 
that the ATE method is a one-pot procedure and that the benzene extraction step used in 
the Bolton-Hunter methodology is not required.  
The incorporation of 125I in the ATE labelling agent was controlled with Radio-HPLC 
before addition of the VLPs. A solid phase radio-binding assay was established and used 
in comparison with ELISA of non-labeled VLPs to verify that the labeling did not affect 
the VLP binding specificity to saliva samples. 
3.5.3. Quartz crystal microbalance with dissipation (QCM-D) monitoring  
The chromatogram binding assay is an ideal tool when screening GSLs for protein 
interactions. However, when further characterizing GSL-protein interactions, supported 
lipid bilayers provide a milieu more resembling the dynamic environment in the cell 
membrane.  
Quartz crystal microbalance with dissipation (QCM-D) monitoring is an efficient method 
to study protein binding to GSLs incorporated in laterally fluid supported lipid bilayers 
(Fig. 14). QCM-D is an extension of QCM (Rodahl et al. 1995). The basis of both 
methods is the piezo electric properties of quartz crystals (Andreas Janshoff 2000). Due to 
this property an external electric field induces mechanical stress in quartz crystals. By 
cutting the crystals in a specific angle, a deformation in shear-mode may be obtained. If 
an alternating electric field is applied across the crystal, it is driven into mechanical 
oscillation and at certain frequencies resonance occurs. Importantly, the resonance 
frequency is dependent on the mass of the crystal. Adsorption of an object to the crystal 
therefore induces a change in the resonance frequency. This change is as a first 
approximation proportional to the mass coupled to the crystal. The resonance frequency, f, 
may be obtained by studying the decay of a free oscillation induced by a pulse of 
alternating current. By also recording the life time of the oscillation, information on 
changes in energy dissipation or the dampening, D, of the oscillating system may be 
obtained. The dampening gives information about the rigidity of the adsorbed object and 
is the basis for the QCM-D extension (Hook et al. 1998). Measurements of the D 
parameter can for instance be used to distinguish adsorbed lipid vesicles, inducing high 
dampening, from planar bilayers, inducing little dampening (Keller & Kasemo 1998). The 
combined f and D measurements make QCM-D well suited for studies of supported lipid 
bilayers as the formation of the bilayer from lipid vesicles may be continuously followed 
over time (Hook et al. 2008). 
QCM-D chip
Quartz crystal
Electrode
SiO2
Phospholipid bilayer
with glycosphingolipids
 
Figure 14 
Schematic representation of GSLs in a supported lipid bilayer formed on a QCM-D chip. 
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QCM-D provides label-free monitoring of the kinetics of binding to surfaces. An 
estimation of the coupled mass in terms of the number of interacting molecules is 
however complicated by the influence of water coupled to the adsorbed molecules. In that 
perspective, new instruments combining QCM-D with surface plasmon resonance or 
reflectometry are promising (Reimhult et al. 2004, Wang et al. 2008). 
QCM-D together with supported lipid bilayers was used in Paper IV. In these studies, a 
Q-Sense E4 instrument (Q-Sense AB, Västra Frölunda, Sweden) with 4 parallel 40 ?l 
sample chambers was used. The working temperature for this instrument may be adjusted 
between 18?C and 45 ?C. Our experiments were performed at 22 ?C.  
Normally, QCM-D experiments are performed in flow mode, keeping the bulk 
concentration of the analyte constant. However, because of limited amounts of VLPs our 
experiments were performed in batch mode. The concentration of VLPs used was in the 
same order of magnitude as in the CBA experiments with antibody detection (Paper IV). 
Each QCM-D experiment with bilayers containing 10 wt% of GSLs required 5 ?g of 
GSLs per chamber. This is similar to the amount of pure GSLs used per lane in the CBA 
(2-5 ?g) (Paper III and IV).  
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4. Results and discussion 
When this project was initiated the first challenge study clearly demonstrating resistance 
of non-secretors to infections with the Norwalk virus had just been published (Lindesmith 
et al. 2003). Additionally, binding studies had suggested that a large number of norovirus 
strains recognize secretor gene dependent glycans (Harrington et al. 2002a, Huang et al. 
2003). The next step was to investigate whether secretor status was associated with 
susceptibility to natural norovirus infections. We addressed this question in two studies. 
In the first one, symptomatic and asymptomatic individuals in authentic norovirus 
outbreaks were genotyped for secretor status (Thorven et al. 2005). This study revealed 
that among 53 symptomatically infected individuals not a single one was a non-secretor. 
The distribution of secretor status in this group was significantly different from the 20% 
non-secretors among 104 Swedish blood donors (p<0.0002) and the 29% non-secretors 
among the 62 asymptomatic individuals (p<0.00001) (Fisher’s exact test). In the second 
study, we investigated concentrations of norovirus specific IgG antibodies in plasma from 
Swedish blood donors (Paper I). Our hypothesis was that if non-secretors are protected 
from norovirus infection, they should have lower titers of antibodies to the virus than 
secretors. 
4.1. Antibody titers to norovirus GII correlate with secretor status 
(Paper I) 
Titers of norovirus specific IgG antibodies were assayed in plasma samples from 105 
Swedish blood donors. These donors constitute a uniquely well-characterized material 
considering ABO(H) histo-blood group glycans. They have been genotyped for FUT2 and 
FUT3 status and phenotyped for ABO and Lewis blood groups on erythrocytes (Larson et 
al. 1999). Norovirus specific IgG antibody titers were determined in an ELISA using 
immobilized VLPs from the Houston strain as antigen. This strain belongs to genocluster 
GII.4, which has been the dominating genocluster in outbreaks during recent years 
(section 1.1.5). 
The result showed that the non-secretors had lower antibody titers than secretors 
(p<0.0001, Mann-Whitney) and were also more often antibody negative (p<0.05, Fisher’s 
exact test). However, some non-secretors had high antibody titers (>1600), suggesting 
that secretor independent strains may exist. No significant difference in antibody 
prevalence or titers was identified between homozygous (SeSe) and heterozygous 
secretors (Sese). In addition, no significant differences were found between FUT3 
genotypes or different ABO phenotypes, neither in the whole material nor among the 
secretor-positive individuals. To exclude the possibility that secretor status was associated 
with susceptibility to viral infections in general, 63 randomly selected plasma samples 
were assayed for IgG antibody titers also towards rotavirus. No correlation of IgG titers 
with FUT2, FUT3 or ABO blood groups was found in this case. 
The identified association between antibody titers and secretor status does not only reflect 
GII.4 strains, but also other strains giving rise to antibodies cross-reacting with the 
Houston VLP. In contrast to outbreak studies, where susceptibility to one strain at the 
time is investigated, this study thus investigated susceptibility to a number of strains 
simultaneously. However, to determine which and how many strains is not trivial, since 
immunity to norovirus is complex (section 1.1.10). We concluded that non-secretors are 
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significantly less prone to be infected with GII noroviruses than secretors. This conclusion 
supports the hypothesis that non-secretors are relatively, but not absolutely, resistant to 
norovirus infection. In addition, our study suggests that secretor and non-secretor 
dependent virus strains have common antigenic epitopes. 
Recently, we identified one non-secretor (se428se428) among 116 symptomatically infected 
individuals in a GII.4 norovirus outbreak (Carlsson et al. 2009a). RT-PCR was used to 
demonstrate the presence of norovirus in the stools of the symptomatically infected non-
secretor, who was also phenotyped on saliva as Lea+b-. In addition, ELISA binding studies 
demonstrated that the outbreak virus recognized saliva from one non-secretor individual. 
The study suggests that non-secretors can indeed get symptomatically infected by GII.4 
viruses. In addition, one GII.4 VLP (2002a) has been demonstrated to bind to saliva 
samples from both secretors and non-secretors (Lindesmith et al. 2008). 
4.2. Human noroviruses recognize SLex (Paper II) 
To map the glycan binding characteristics of norovirus VLPs, an ELISA using 
immobilized neoglycoproteins or saliva samples was established. The first VLP to be 
investigated in the assay was Chron1. This VLP was constructed from the first viral 
isolate from the chronically infected patient described in section 1.1.2 and 1.1.10. 
Surprisingly, the Chron1 VLP showed a strong interaction with SLex-HSA. Initially, we 
thought that this novel binding specificity was related to the chronic infection caused by 
the virus, as SLex is a well known marker for inflamed tissue (section 1.2.3). However, 
subsequent experiments with the Dijon VLP, belonging to the common GII.4 cluster, 
demonstrated that also this VLP recognized SLex-HSA. In contrast, the Norwalk strain 
(GI.1) did not recognize this sialylated conjugate. The characteristics of the identified 
sialic acid dependent binding specificity were reported in Paper II. This paper also 
describes the binding properties of the Chron1 and Dijon VLPs to secretor gene 
dependent neoglycoproteins and to saliva samples from individuals representing different 
ABO(H) histo-blood groups. 
A number of 81 individuals, who donated plasma samples used in Paper I, also donated 
saliva samples. In order to further extend the ABO(H) and Lewis histo-blood group 
characterization of the donors, the saliva samples were phenotyped for A, B, Lea, Leb and 
SLex antigens, before being assayed for VLP binding. As the saliva binding 
characteristics of the Norwalk strain had already been well described (Marionneau et al. 
2005), it was not included in the analysis. The result showed that both the Chron1 and the 
Dijon VLP recognized saliva samples from secretor-positive individuals only. In addition, 
both VLPs bound stronger to saliva from secretor-positive A, B and AB individuals 
compared to O individuals (Chron1, p<0.0001; Dijon p<0.001, Mann-Whitney). The 
Chron1 strain, furthermore, bound stronger to saliva from B than from A2 secretors 
(p<0.01). This VLP also showed a larger interindividual variance in binding than the 
Dijon VLP. Both the total variance and the variance within each blood group were larger 
for the Chron1 strain.  
The saliva binding pattern determined for the Dijon strain is in agreement with most GII.4 
strains studied (Huang et al. 2005, Shirato et al. 2008) even though, for some GII.4 
strains, other binding patterns have been reported (Lindesmith et al. 2008). The Chron1 
strain has a somewhat broader saliva binding pattern than other GII.3 strains, as it 
recognizes saliva from some secretor-positive blood group O individuals. Of the other 
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GII.3 strains described, the Paris Island and r336 strains recognize saliva from secretor-
positive blood group A and B, but not O individuals whereas the Mexico strain recognizes 
saliva from A, but not O or B individuals (Huang et al. 2005, Shirato et al. 2008) (Table 
3). The recognition of blood group O structures by the Chron1 strain was further 
supported by the fact that the chronically infected patient was a secretor and Lewis 
positive blood group O individual. ?
The binding to specific glycans was studied using neoglycoproteins, either immobilized 
directly in the ELISA or used as inhibitors in the saliva ELISA. The sialic acid dependent 
binding specificity identified for the Chron1 and the Dijon strain in these experiments is 
summarized in Table 5. Three sialylated structures, SLex, SdiLex and S Type 2, on 
neoglycoproteins were shown to bind to the two VLPs. The binding to SLex-HSA was 
strictly sialic acid dependent as Lex-BSA did not bind. However, non-sialylated type 
2-HSA showed weak binding to the Dijon VLP. The binding of both VLPs to S Type 
2-HSA demonstrated that the Fuc? residue of SLex is not absolutely required for binding. 
A terminal sialic acid in itself was however not enough for binding since SLea-HSA did 
not bind. The lack of binding to SLea-HSA suggests that the binding is specific since the 
only difference between SLex and SLea is a switch in positioning between the Fuc? 
residue and the Neu5Ac?2,3Gal? disaccharide to GlcNAc. The binding of SdiLex-HSA 
illustrated that modifications at the reducing end of the SLex pentasaccharide may be 
tolerated. As suggested by the saliva binding experiments, the Chron1 and Dijon VLPs, in 
addition to the sialylated structures, recognized secretor gene dependent glycans. The 
?1,2-Fuc-dependent binding specificity was reflected by binding to the Leb conjugate for 
the Chron1 strain and to the H type 1, Leb, Ley, and B trisaccharide conjugates for the 
Dijon strain. In contrast, the Norwalk strain did not recognize the neoglycoproteins with 
Table 5 Binding activity for various neoglycoproteins towards the  
Chron1 and Dijon VLPs. The data has been compiled from the direct 
binding and inhibition experiments presented in Paper II. 
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sialylated glycans. The Norwalk VLP bound strongly to the H type 1 and Leb conjugates, 
and weakly also to the Ley and H type 2 conjugates.  
The identified sialic acid dependent binding specificity is distinguished from the secretor 
gene dependent binding, as FUT2 is not involved in the biosynthesis of SLex, S type 2 or 
SdiLex. Nevertheless, the saliva samples were assayed for SLex using the CSLEX-1 
antibody to rule out the possibility that the expression of this antigen was dependent on 
secretor status. This experiment showed that SLex could be detected in saliva samples 
from both secretor and non-secretors in analogy with a previous study (Thomsson et al. 
2005). It could be concluded that saliva samples from at least some non-secretors have 
detectable levels of SLex but still do not bind to the Chron1 or Dijon VLPs. To verify that 
these VLPs do not recognize the SLex epitopes found in saliva, the three saliva samples 
with the highest reactivity with the CSLEX-1 antibody were assayed at a 10-fold 
increased coating concentration. Even at this high concentration, no binding of either of 
the VLPs was observed. Furthermore, the saliva sample with the highest reactivity with 
the CSLEX-1 antibody was titrated together with the SLex-HSA conjugate and separately 
assayed with the CSLEX-1 antibody and the Chron1 VLP. This experiment indicated that 
the amount of SLex in the saliva sample would be sufficient for VLP binding, suggesting 
a difference between the VLP and the antibody in their specificity for the SLex epitope. 
The SLex structure on the neoglycoprotein is the full length hexasaccharide found on 
GSLs, even though the innermost Glc residue is ring-opened to facilitate the conjugation 
to the protein. In contrast, the most abundant SLex epitope in saliva mucins is the core 
2-based structure. This structure has the same terminal SLex tetrasacchride as the GSL 
structure, but differs from the GSL epitope in the rest of the structure. The presentation of 
the SLex epitope varies between different core structures, which is illustrated by the large 
number of antibodies directed towards specific SLex structures available (Clark et al. 
1998). Studies of the core fucose substitution of N-glycans have demonstrated that 
carbohydrate substitutions distant from the binding epitope may alter the presentation and 
lectin binding properties of the epitope (section 1.3.5). A complementary explanation for 
the difference in VLP binding observed between SLex-HSA and SLex-expressing non-
secretor saliva could be that the multivalency of the conjugates, but not of the saliva 
mucins, are optimal for VLP binding (section 1.3.4). 
It is interesting to note that many other viruses recognize sialylated carbohydrate 
structures (Olofsson & Bergstrom 2005). Recently, Taube et al. demonstrated that murine 
noroviruses use the ganglioside GD1a (see Fig 10 for structure) as receptor (Taube et al. 
2009). Previously, ?2,6-linked sialic acid on an N-linked glycan has been shown to be 
part of the receptor for feline calicivirus (Stuart & Brown 2007). Thus, binding to 
sialylated glycans seems to be a common theme for several caliciviruses. As a 
speculation, SLex or structural analogues could function as co-receptors for some human 
norovirus strains. If this is the case it could have implications for the identification of the 
target cells in the intestine as well as functional cells for in vitro cultivation of the virus. 
For numerous viruses, the distribution of receptors and co-receptors is crucial for the 
tissue tropism (section 1.3.2). Interestingly, the herpes-simplex virus type-1 and varicella-
zoster virus were recently demonstrated to induce SLex expression on target cells through 
upregulation of host fucosyltransferases (Nystrom et al. 2007, Nystrom et al. 2009). 
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An obvious parallel to the dual binding specificities of norovirus is the adhesion 
characteristics of H. pylori. Just like norovirus, this bacteria is an intestinal pathogen 
recognizing both ?1,2-fucosylated glycans and sialylated Lewis antigens. The expression 
of SLex in the gastric epithelium is induced during chronic H. pylori infections, 
suggesting the bacterium to induce glycans for attachment (Mahdavi et al. 2002). 
Recently a mechanism for the induction involving upregulation of the expression of 
?3GlcNAcTV (converting Gal?4Glc?Cer to GlcNAc?3Gal?4Glc?Cer) was suggested for 
certain H. pylori strains (Marcos et al. 2008). In addition, the interaction between H. 
pylori and SLex has been shown to be essential for the bacterial stimulation of neutrophils 
(Unemo et al. 2005). This stimulation is an important virulence mechanism for the 
bacterium as it results in production of reactive oxygen species causing oxidative damage 
of the gastric epithelium. An opposite effect on neutrophils involving SLex has been 
suggested for the Staphylococcal superantigen-like protein 5 (SSL5). First, SSL5 was 
demonstrated to prevent neutrophil rolling by binding to SLex on PSGL-1 (Bestebroer et 
al. 2007). Thereafter, SSL5 was also shown to bind to G-protein coupled receptors on the 
neutrophils in a SLex dependent manner. This interaction blocked the binding of 
chemokines to the receptors and thus inhibited neutrophil activation by chemotactic 
factors (Bestebroer et al. 2009). 
Irrespective of the biological function, the recognition of SLex by noroviruses may be 
exploited for anti-adhesion therapy. Our inhibition experiments demonstrated that at 10 
?g/mL SLex-HSA was able to completely inhibit the binding of both the Chron1 and the 
Dijon VLP to saliva. The saliva sample used was from an ABLeSe individual, thus 
 
Figure 15  
Schematic presentation of SLex-HSA conjugates and norovirus VLPs to visualize size ratios 
and possible mechanisms of interactions. The HSA molecules are colored yellow with the 
attached SLex oligosaccharides in green. The monomers in the VLPs are visualized by 
coloring the three monomers in the crystallographic unit cell in red, blue and beige 
respectively. The coordinates for the structures of the Norwalk VLP and HSA were adopted 
from Prasad et al. (1999) and Sugio et al. (1999). SLex pentasaccharides were modeled using 
Sweet2 (Bohne et al. 1999) and attached to randomly selected lysine residues on the HSA 
surface via a ring-opened Glc residue conjugated to an aminophenylethyl spacer. The picture 
was constructed using the Chimera package. 
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theoretically presenting a maximum of potential receptor glycans. In these experiments, 
inhibition of neither the Chron1 nor the Dijon VLP was seen with the H type 1- or the 
Leb-HSA conjugate, even though these conjugates inhibited the binding of the Norwalk 
VLP. Thus, the Leb conjugate bound to both Chron1 and Dijon VLP if it was immobilized 
in the ELISA, but did not show any inhibition potential as a free conjugate in solution. 
This discrepancy may indicate that the accessible number of Leb epitopes on one single 
HSA conjugate is not large enough to form a binding of a sufficient valency. 
Interestingly, the SLex conjugate has a lower valency than the Leb conjugate (13 vs. 29 
glycans/protein). The multivalency of the SLex conjugate makes it difficult to determine 
whether the sialylated structures accommodate the same binding site as the 
?1,2-fucosylated glycans. Figure 15 shows a schematic visualization of the interaction 
between VLPs and SLex-HSA conjugates. The picture shows that the size of SLex-HSA is 
larger than the capsid protein monomer and that the conjugate might therefore block a 
second binding site by steric hindrance without actually binding to it. The picture also 
shows that SLex-HSA is large enough to simultaneously interact with several monomers 
on the same VLP to allow a multivalent interaction. In addition the size ratios of the VLPs 
and the HSA conjugates suggest VLP aggregation to be a potential mechanism of 
inhibition. 
4.3. Human noroviruses recognize glycosphingolipids (Paper III and 
IV) 
GSLs have been shown to function as true receptors for a number of viruses and bacterial 
toxins (section 1.3.1). To investigate whether norovirus recognizes ABO(H) histo-blood 
group active GSLs, Norwalk VLPs were studied using a thin layer chromatogram binding 
assay (CBA) (Paper III). For detection, the VLPs were 125I-labeled using an activated tin-
containing ester (ATE). A solid phase radio-binding assay was used to verify that the 
labeling did not affect the VLP binding specificity to saliva samples. In addition, the 
binding results for the H type 1 and the Lea GSL were validated in Paper IV, using 
antibody detection of non-labeled VLPs in the CBA.  
4.3.1. The Norwalk virus recognizes glycosphingolipids terminated with A, 
H and difucosylated Lewis, but not B histo-blood group epitopes (Paper III) 
Using the CBA, we could determine the binding pattern of the Norwalk VLP to many of 
the neutral GSLs of the lactotetra (type 1) and neolactotetra (type 2) series. For the type 1 
chain structures, the VLP showed a secretor gene dependent binding pattern and did not 
recognize the precursor (lactotetra) or Lea. The VLP bound to the ?1,2-fucosylated 
structures H type 1, Leb, A type 1 and ALeb, but not to B type 1 or BLeb. An analogous 
binding pattern was seen for the type 2 structures with binding to H type 2, Ley, A type 2 
and ALey, but not to Lex. The determined GSL binding pattern is in agreement with the 
pattern expected from saliva binding studies and challenge studies with the Norwalk virus 
(section 1.5.1). The determined pattern is essentially in agreement also with binding data 
for specific glycans obtained in ELISA studies using PAA and HSA neoglycoconjugates 
(Harrington et al. 2002a, Huang et al. 2005, Hutson et al. 2003). Norwalk VLP binding to 
blood group A and B structures which are type 1 and type 2 specific, as well as 
difucosylated, has not been assayed before. 
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A difference between the Norwalk virus binding pattern to GSLs and to 
neoglycoconjugates was the weak binding of the Leb GSL compared to the H type 1 GSL. 
Binding studies using PAA-conjugates have suggested these structures to be of similar 
binding strengths (Harrington et al. 2002a, Huang et al. 2005, Hutson et al. 2003). In our 
own inhibition studies with the Norwalk virus, Leb-HSA was an even better inhibitor than 
H type 1-HSA (Paper II). However, in agreement with the weak binding of the Leb GSL, 
the free Leb tetrasaccharide has been reported to be unable to inhibit Norwalk VLP 
binding to tissue sections while near-complete inhibition was seen with H type 1 
trisaccharide under the same conditions (Marionneau et al. 2002). The discrepancy in Leb 
binding suggests differences in the presentation of glycans between different conjugates, 
highlighting the necessity to use different conjugates to completely map binding 
specificities. Differences in glycan presentation between different glycoconjugates have 
also been noticed by others in the norovirus field (Huang et al. 2009, Shirato et al. 2008). 
In analogy with the binding to purified A- and H-, but not B-terminated GSLs, the 
Norwalk VLP recognized a large number of structures in mixtures of GSLs from blood 
group O, A1 and A2, but not from blood group B erythrocytes. In the B fraction, only one 
weak VLP binding band in the seven sugar region could be detected. This band most 
likely corresponds to an elongated H type 2 GSL. Using antibodies, the presence of H 
epitopes was demonstrated in the erythrocyte B fraction as well as in meconium GSLs 
from a secretor-positive B individual. Binding to such residual H epitopes, not converted 
to B epitopes, may explain the susceptibility of some secretor-positive B individuals to 
Norwalk virus infection. This explanation is also in agreement with the binding of 
Norwalk VLPs to saliva samples from some secretor-positive blood group B individuals 
only. 
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Figure 16 
The biosynthetic scheme of the type 1 and type 2 ABO(H) histo-blood group GSLs with the 
structures demonstrated to bind to the Norwalk VLP encircled. 
 47 
When comparing the binding to the A1 and A2 erythrocyte fractions an A1 specific band 
was seen in the seven sugar region. This band most likely corresponds to the A type 4 
(Globo A) GSL (GalNAc?3(Fuc?2)Gal?3GalNAc?3Gal?4Gal?4Glc?Cer), typically 
found in A1 but not in A2 individuals (section 1.2.3). 
A terminal GalNAc is not enough for binding of the Norwalk virus (Paper III) 
The X-ray structures of the P dimer of the Norwalk virus capsid protein in complex with 
the A trisaccharide and the H type 1 pentasaccharide revealed that the ?Fuc residue was 
minimally involved in the binding of the A epitope (Choi et al. 2008). However, the lack 
of Norwalk VLP binding to the globoside (GalNAc?3Gal?4Gal?4Glc?Cer) and the 
Forssman (GalNAc?3GalNAc?3Gal?4Gal?4Glc?Cer) GSL in the chromatogram binding 
assay, suggests that a terminal GalNAc is not enough for binding. 
4.3.2. The Norwalk and Dijon strains recognize supported lipid bilayers 
containing H type 1 glycosphingolipids (Paper IV) 
In paper IV supported lipid bilayers were used to study the interaction between GSLs and 
norovirus VLPs in an environment resembling the plasma membrane. Quartz crystal 
microbalance with dissipation (QCM-D) monitoring is a suitable method for binding 
studies involving supported lipid bilayers. This is mainly because the parameters 
monitored provide unique signatures for a successful formation of a continuous fluid 
membrane. In addition, QCM-D provides label free monitoring of the binding kinetics. 
The binding of Norwalk and Dijon VLPs to supported lipid bilayers with 10 wt% of either 
H type 1 or Lea GSL was studied using QCM-D. In complete agreement with CBA 
experiments, both VLPs bound to bilayers containing H type 1, whereas no binding could 
be detected to bilayers containing Lea. Thus, human noroviruses recognize GSLs both on 
thin layer chromatograms and in supported lipid bilayers. This suggests that GSLs can be 
considered as potential receptors. The idea is supported by the recent demonstration of 
gangliosides as receptors for murine norovirus (Taube et al. 2009). 
Analysis of the VLP binding kinetics to the H type 1 bilayers revealed differences in total 
resonance frequency shifts (?f) and equilibrium time between the two norovirus strains. 
These differences were probably caused by differences in concentrations of active VLPs. 
By plotting the monitored response in resonance frequency, f, versus the change in energy 
dissipation, D, the time and thus the VLP concentration was eliminated as explicit 
parameters. Such plots revealed a lower ?f/?D ratio for the Norwalk than the Dijon strain 
indicating that the Norwalk VLPs forms a more rigid structure together with the lipid 
bilayer. 
To further compare the binding properties, binding of Norwalk and Dijon VLPs to 
bilayers containing different amounts of H type 1 GSLs was studied. In order to 
compensate for possible domain formations, Lea was added to achieve a total GSL 
concentration of 10 wt% in all bilayers. However, identical results were obtained in 
experiments without addition of Lea. An IgG1 antibody directed against H type 1 was 
included to confirm the availability of the GSL in the membrane. For both VLPs, the 
binding was dependent on the concentration of H type 1 in the bilayer. In support of 
multivalency, both strains showed a threshold concentration of H type 1 below which no 
binding was observed. Interestingly, the threshold concentration was one order of 
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magnitude larger for the Dijon compared to the Norwalk strain. The larger value observed 
for the Dijon strain suggests that this VLP must interact with a larger number of GSLs for 
detectable attachment to the lipid bilayer. No threshold concentration was observed for 
the antibody. 
We propose a stepwise model for the interaction where the VLPs initially bind only a few 
GSLs but where the binding is subsequently strengthened by additional GSLs recruited by 
lateral diffusion in the bilayer (Fig. 17). At low GSL concentrations, the distance between 
the GSLs is too large to provide multivalent binding. The monovalent interaction at such 
densities is too weak to provide adhesion in a time scale long enough for additional GSLs 
to diffuse into the interaction area. As the concentration of GSLs increases, the distance 
between the GSLs decreases. Thus, a VLP approaching the bilayer gets in contact with a 
larger number of GSLs. Moreover, the time required for additional GSLs to diffuse into 
the interaction area decreases with increasing GSL concentration. At concentrations above 
the threshold value, VLPs arriving to the bilayer stay there long enough for additional 
GSLs to strengthen the interaction. These additional GSLs make the interaction 
essentially irreversible. 
The difference in threshold concentration identified between the Norwalk and the Dijon 
strain suggests the latter to have a lower affinity for the H type 1 GSL. This difference is 
probably a reflection of the different binding sites used by GI.1 and GII.4 strains for 
binding to the H type 1 glycan (Cao et al. 2007, Choi et al. 2008). 
For the Norwalk strain a maximal shift in resonance frequency was obtained at 1 wt% of 
H type 1. No such maximum was observed for the Dijon strain, up to 10 wt% of H type 1. 
 
Figure 17 
Schematic model illustrating the adhesion of Norwalk and Dijon VLPs to bilayers containing 5 wt% 
of H type 1 and 5 wt% of Lea GSLs. Initially the VLPs bind only a few H type 1 GSLs, but the binding 
is subsequently strengthened by additional H type 1 GSLs moving into the interaction area. The 
number of GSLs needed to maintain at the bilayer is larger for the Dijon strain than for the Norwalk 
strain. At the H type 1 concentration shown, the binding was limited by VLP depletion for the 
Norwalk strain but by ligand depletion for the Dijon strain. 
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The resonance frequency shifts are measured when the binding process has reached 
equilibrium. As the experiments were performed in stationary reaction chambers, the 
equilibrium may be caused by depletion of either VLPs or GSLs. At low GSL 
concentrations, the GSLs are the limiting factor, whereas at high GSL concentrations the 
VLPs are limiting. The observation of a maximal shift for the Norwalk, but not the Dijon 
strain, is consistent with a lower concentration of active VLPs for the Norwalk strain. 
Thus, at 5 wt% of H type 1 in the bilayer, the binding process seems to be limited by VLP 
depletion for the Norwalk strain, but by ligand depletion for the Dijon strain (Fig. 17). 
To analyze the binding kinetics, bi-exponential functions were fitted to the resonance 
frequency curves obtained for the bilayers with different concentrations of H type 1. 
These functions resolved the binding processes into a fast and a slow phase. An analysis 
of the rate constants for the fast phase revealed a sharp transition from non-binding to 
binding for both strains at their respective threshold concentrations. A maximal rate was 
reached for the Norwalk VLP at 1 wt% H type 1 and for the Dijon VLP at 5 wt% H type 
1. Thus, even though no maximal shift in resonance frequency was identified for the 
Dijon strain a maximal binding rate was identified through this kinetic analysis. 
The sharp transition from non-binding to binding at the threshold concentration, suggests 
the VLPs to be precise sensors of receptor density. Data in support of a biological 
relevance for such a threshold effect in relation to susceptibility to infection is provided 
by studies of the related lagovirus, RHDV. Young rabbits are protected from infection 
with this virus, which attaches through recognition of H type 2. The expression of the 
glycan is low in young rabbits, but increases with age. Interestingly, the increase in 
expression of H type 2 is paralleled by an increase in susceptibility to infection with 
RHDV (Ruvoen-Clouet et al. 2000). 
The identification of a threshold concentration for human noroviruses suggests that 
individuals with a low expression of the potential glycan receptors may be protected also 
from high concentrations of the virus. In analogy, the difference in threshold 
concentration between the Norwalk and Dijon strains, could suggest that some individuals 
may be susceptible to infection with the Norwalk but not the Dijon strain. However, 
glycan binding viruses must not only get in contact with glycans on the target cell, but 
also avoid getting trapped on mucins and other decoy receptors. For viruses with receptor 
destroying enzymes, the balance between receptor binding and destruction is crucial. For 
instance, the requirement for a delicate balance between the hemagglutinin and 
neuraminidase activities of influenza A and B virus is well documented (Wagner et al. 
2002). Many viruses lacking receptor destroying enzymes avoid getting stuck by 
possessing a weak affinity for their receptors (Harrison 2007). Such an inverse correlation 
between binding affinity and virulence have been described for murine polyomavirus and 
parvovirus, both recognizing sialic acid bearing glycans (Bauer et al. 1995, Nam et al. 
2006). In analogy with the weak affinities observed for these viruses, the threshold 
concentrations identified for noroviruses may reflect a mechanism for the viruses to avoid 
decoy receptors. It has been hypothesized that the wide binding specificity typical for 
GII.4 norovirus strains is linked to their clinical dominance (Le Pendu et al. 2006, Shirato 
et al. 2008). Another speculation is that an optimal affinity for the receptor glycans may 
contribute to the high prevalence of this genocluster. 
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4.4. Conclusions 
To summarize, our studies have extended the knowledge of the diversity of the histo-
blood group glycans recognized by human noroviruses. We have strengthened the 
evidence for the existence of strains capable of infecting non-secretors, and at the same 
time shown that secretors are much more prone to be infected by GII strains (Paper I). 
Additionally, we have for the first time identified SLex and some of its structural 
analogues as potential co-receptors for GII strains (Paper II). The ability of SLex-HSA 
conjugates to inhibit binding of Chron1 (GII.3) and Dijon (GII.4) VLPs to saliva points to 
new strategies for anti-adhesion therapy. Additionally, we have shown that noroviruses do 
not only recognize secretor gene dependent glycans on glycoproteins, but also on GSLs. 
In Paper III we demonstrated that the Norwalk (GI.1) VLP recognizes blood group A and 
H, but not B, terminated GSLs of both the type 1 and type 2 series. In paper IV we 
validated the binding of GSLs in supported lipid bilayers using QCM-D. Thus, VLPs 
from the Norwalk and Dijon strains were shown to bind to bilayers containing H type 1, 
whereas no binding was observed to those with Lea. In support of multivalency, both 
strains showed a threshold concentration of H type 1 below which no binding was 
observed. The threshold concentration was higher for the Dijon strain, suggesting a 
weaker affinity to the H type 1 GSL for that strain. 
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5. Ongoing and further studies 
5.1. Docking of histo-blood group ABO active saccharides with the 
norovirus VA387 capsid protein 
The crystal structures of the P dimers of the capsid protein of the VA387 norovirus strain 
in complex with the histo-blood group A and B trisaccharides provide structural 
information about the binding pocket of GII.4 strains (Cao et al. 2007). However, a 
complete understanding of the wide binding specificity typical for GII.4 strains requires 
structural information also for other histo-blood group glycans. In addition, a complete 
map of the amino acids involved in the recognition of the potential receptor glycans 
would facilitate structure-based inhibitor design. Since amino acids, interacting with an 
inhibitor may be mutated to confer resistance to the drug, an ideal inhibitor should have a 
ligand footprint not significantly exceeding the footprint of the natural ligands. 
Together with P. G. Nyholm and co-workers, Biognos AB, Gothenburg (Koppisetty et al. 
2009), we have computationally explored the fit of the VA387 capsid protein with a set of 
histo-blood group glycans containing an ?1,2-linked fucose residue. Docking of ?-fucose 
using Glide XP was in agreement with the crystal structure of the A and B trisaccharides 
indicating a distinct binding site for fucose. Because docking software has problems with 
large glycans we used a simple superimposition of the extended structures with the 
terminal ?1,2-linked fucose in the binding site followed by molecular dynamics (MD) 
using Amber 8.0 (Case et al. 2005) with position restraints on the fucose. The trajectories 
of the MD simulations were analyzed and the relative binding energies were calculated 
with the Glide XP scoring function v5 (Schrödinger, LLC, NY). The result suggests that a 
wide variety of ABO and Lewis active type 1 chain structures may be well accommodated 
in a similar mode in the VA387 binding site. In contrast, A and H antigens bind to the 
Norwalk virus binding pocket in different orientations (Choi et al. 2008). Calculations of 
the binding energies of the complexes from the MD simulations suggested that in addition 
to the Fuc?1,2, the GalNAc?/Gal?1,3 of the A and B terminated structures made strong 
interactions with the VA387 protein. The difucosylated structures Leb, ALeb and BLeb 
were well compatible with the binding site, but the Fuc?1,4 modification had only a 
minor influence on the interaction energy. This observation is in agreement with saliva 
binding studies of the VA387 VLP suggesting the influence of Lewis status to be small 
(Huang et al. 2003, Huang et al. 2005). In addition, MD simulations of the H type 3 
trisaccharide suggested that the type 3 chain is also compatible with the binding site. 
Notably, the O1 of the H type 3 GalNAc? pointed into the bulk medium. The 
accessibility of this oxygen may be the basis for the strong binding reported for 
neoglycoconjugates with the H type 3 trisaccharide (Huang et al. 2005). The structural fit 
of the ?1,2-fucosylated glycans investigated was in agreement with mutational analysis of 
the VA387 binding site (Tan et al. 2008c). 
5.2. Identification of the biological function of the SLex-related binding 
specificity 
In search for a biological function of the SLex-related norovirus binding specificity 
histochemical binding studies using tissues with high expression of SLex will be initiated 
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together with Prof. Jacques Le Pendu and coworkers, INSERM, Nantes, France. These 
studies will include FACS analysis of VLP binding to SLex-expressing cultured cells. 
To investigate whether norovirus recognizes sialylated GSLs, gangliosides are being 
screened for VLP binding using the CBA in collaboration with Prof. Susann Teneberg, 
University of Gothenburg. 
5.3. Further characterization of VLP binding to glycosphingolipids in 
supported lipid bilayers using QCM-D 
QCM-D will be used to further characterize the interaction between norovirus VLPs and 
GSLs in supported lipid bilayers. Specifically, the influence of the composition of the 
bilayer in terms of different phospholipids, sphingomyelin and cholesterol will be 
investigated at different temperatures. In addition, the QCM-D assay will be evaluated for 
studies of inhibitors of VLP attachment. 
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6. Populärvetenskaplig sammanfattning på 
svenska 
Norovirus orsakar den s.k. vinterkräksjukan, som kännetecknas av kaskadkräkningar och 
diarré. Medvetenheten om norovirus har ökat under senare år, sannolikt beroende på en 
kombination av införandet av känsligare metoder för virusdiagnostik och uppkomsten av 
mer aggressiva virusstammar. Sedan 2002 har världsomspännande epidemier av 
norovirusinfektioner inträffat ungefär vartannat år. Idag anses norovirus vara den 
mikroorganism som orsakar flest utbrott av magtarm-infektion (kräkningar och diarré) i 
världen. Viruset orsakar varje år upp till 200 000 dödsfall bland barn i u-länder. 
Inga vaccin eller läkemedel finns ännu mot norovirus. Upptäckten att norovirus sannolikt 
använder ABO-blodgrupper på cellytan för att ta sig in i cellen har lett till försök att hitta 
molekyler som blockerar interaktionen mellan viruset och cellytan. Sådana molekyler 
skulle kunna hindra viruset från att ta sig in cellen och därmed förhindra virusinfektionen. 
Vi har upptäckt att norovirus från den vanligaste genogruppen (GII) inte bara binder till 
ABO-blodgrupper utan även till en annan grupp kolhydrater, som kännetecknas av att de 
ytterst bär monosackariden sialinsyra. Inhibitionsförsök visade att proteiner som på ytan 
exponerar dessa sialinsyrainnehållande kolhydrater var effektiva hämmare av 
norovirusbindning. Genom att vidare analysera virusets bindningsegenskaper till 
sialinsyrainnehållande kolhydrater hoppas vi kunna utveckla nya hämmare med ännu 
effektivare hämningsförmåga.  
Intressant nog har det visats att individer, som tillhör den femtedel av den europeiska 
befolkningen som är s.k. sekretornegativa, är resistenta mot norovirusinfektioner. 
Sekretornegativa individer saknar det enzym som krävs för att uttrycka ABO-blodgrupper 
på tarmceller och i saliv. Sannolikt beror resistensen hos dessa individer på att viruset 
behöver ABO-blodgrupper för att ta sig in i tarmcellerna. Många virus använder flera 
molekyler för att ta sig in i målcellen. Möjligen är interaktionen med de 
sialinsyrainnehållande kolhydratstrukturerna, som vi upptäckt, också nödvändiga för 
norovirus intrång i celler.  
Vår forskargrupp har tidigare visat att inga sekretornegativa individer fanns bland de 
symptomatiskt sjuka i ett antal svenska norovirusutbrott. Denna avhandling stärker 
kopplingen mellan sekretorstatus och mottaglighet för norovirusinfektion ytterligare 
genom att visa att sekretorpositiva individer har en statistiskt säkerställd högre 
koncentration antikroppar mot norovirus i blodet än sekretornegativa individer. Detta 
tyder på att sekretorpositiva individer haft betydligt fler norovirusinfektioner än 
sekretornegativa individer. Dock så hade vissa sekretornegativa individer betydande 
koncentrationer antikroppar, vilket tyder på att även sekretornegativa kan infekteras av 
vissa norovirusstammar. 
I avhandlingen visas även för första gången att norovirus inte bara binder till 
ABO-blodgrupper på proteiner utan även på lipider, s.k. glykolipider. Glykolipider finns i 
stora mängder i cellmembranet och har för flera virus visats vara sanna receptorer, dvs de 
molekyler som aktivt hjälper viruset in i cellen. Med hjälp av nyutvecklade mätinstrument 
har vi studerat interaktionen mellan norovirus och glykolipider i syntetiska membraner, 
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som liknar cellmembranet. Dessa studier visar att viruset måste interagera med flera 
glykolipider samtidigt, s.k. multivalent bindning, för att fastna på lipidmembranet. 
Sammanfattningsvis beskriver avhandlingen norovirus förmåga att binda till ett antal 
olika mänskliga kolhydrater. Kunskaper om virusets precisa bindingsegenskaper hoppas 
vi ska kunna användas till utveckling av läkemedel som förhindrar virusets intrång i 
cellen. 
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